NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Little J, Wilson B, Carter R, et al. Multigene Panels in Prostate Cancer Risk Assessment. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Jul. (Evidence Reports/Technology Assessments, No. 209.)

Cover of Multigene Panels in Prostate Cancer Risk Assessment

Multigene Panels in Prostate Cancer Risk Assessment.

Show details

Appendix CExcluded Studies

  • Anonymous Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. Br J Clin Pharmacol. 2010;70(2):222–3. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC2911552] [PubMed: 20653675]
  • Anonymous Matrix metalloproteinase-2 polymorphism is associated with prognosis in prostate cancer. Urol Oncol. 2010;28(6):624–7. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 19117773]
  • Abe M, Xie W, Regan MM, et al. Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int. 2011;107(1):126–34. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3010266] [PubMed: 20477822]
  • Adank MA, van Mil SE, Gille JJ, et al. PALB2 analysis in BRCA2-like families. Breast Canc Res Treat. 2011;127(2):357–62. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 20582465]
  • Adeyemo A, Rotimi C. Genetic variants associated with complex human diseases show wide variation across multiple populations. Publ Health Genomics. 2010;13(2):72–9. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2835382] [PubMed: 19439916]
  • Agalliu I, Leanza SM, Smith L, et al. Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population. Prostate. 2010;70(15):1716–27. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC3404133] [PubMed: 20564318]
  • Agalliu I, Suuriniemi M, Prokunina-Olsson L, et al. Evaluation of a variant in the transcription factor 7-like 2 (TCF7L2) gene and prostate cancer risk in a population-based study. Prostate. 2008;68(7):740–7. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2765224] [PubMed: 18302196]
  • Agalliu I, Kwon EM, Salinas CA, et al. Genetic variation in DNA repair genes and prostate cancer risk: Results from a population-based study. Canc Causes Contr. 2010;21(2):289–300. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2811225] [PubMed: 19902366]
  • Agalliu I, Lin DW, Salinas CA, et al. Polymorphisms in the glutathione S-transferase M1, T1, and P1 genes and prostate cancer prognosis. Prostate. 2006;66(14):1535–41. OVID-Embase. Exclude: Candidate gene study. [PubMed: 16921513]
  • Agalliu I, Karlins E, Kwon EM, et al. Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Canc. 2007;97(6):826–31. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2360390] [PubMed: 17700570]
  • Ahn J, Kibel AS, Park JY, et al. Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. Clin Canc Res. 2011;17(5):1075–81. OVID-Embase. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3059497] [PubMed: 21343373]
  • Ahn J, Schumacher FR, Berndt SI, et al. Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3) Hum Mol Genet. 2009;18(19):3749–57. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2742399] [PubMed: 19574343]
  • Ahn J, Berndt SI, Wacholder S, et al. Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet. 2008;40(9):1032–4. OVID-Embase. Exclude: Study Design. [PMC free article: PMC3086200] [PubMed: 19165914]
  • Ahn J, Albanes D, Berndt SI, et al. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis. 2009;30(5):769–76. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2675652] [PubMed: 19255064]
  • Al Khaldi RM, Al MF, Al AS, et al. Associations of single nucleotide polymorphisms in the adiponectin gene with adiponectin levels and cardio-metabolic risk factors in patients with cancer. Dis Markers. 2011;30(4):197–212. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC3825085] [PubMed: 21694446]
  • Al Olama AA, Kote-Jarai Z, Giles GG, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet. 2009;41(10):1058–60. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 19767752]
  • Albayrak S, Canguven O, Goktas C, et al. Role of MMP-1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population. Urol Int. 2007;79(4):312–5. OVID-Medline. Exclude: Test not commercially available. [PubMed: 18025848]
  • Alcazar LP, Arakaki PA, Godoy-Santos A, et al. Estrogen receptor polymorphism and its relationship to pathological process. Am J Med Sci. 2010;340(2):128–32. OVID-Embase. Exclude: Study Design. [PubMed: 20421786]
  • Allin KH, Nordestgaard BG, Zacho J, et al. C-reactive protein and the risk of cancer: A mendelian randomization study. J Natl Canc Inst. 2010;102(3):202–6. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 20056955]
  • Alvarez K, Kash SF, Lyons-Weiler MA, et al. Reproducibility and performance of virtual karyotyping with SNP microarrays for the detection of chromosomal imbalances in formalin-fixed paraffin-embedded tissues. Diagn Mol Pathol. 2010;19(3):127–34. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 20736741]
  • Amankwah EK, Wang Q, Schildkraut JM, et al. Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: A report from the Ovarian Cancer Association Consortium. PLoS One. 2011;6(5):e19642. OVID-Embase. Exclude: Not about prostate cancer. [PMC free article: PMC3103497] [PubMed: 21637745]
  • Amankwah EK, Kelemen LE, Wang Q, et al. Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer. Canc Epidemiol Biomarkers Prev. 2011;20(5):1028–31. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC3176661] [PubMed: 21415361]
  • Amirian ES, Ittmann MM, Scheurer ME. Associations between arachidonic acid metabolism gene polymorphisms and prostate cancer risk. Prostate. 2011;71(13):1382–9. OVID-Embase. Exclude: Candidate gene study. [PubMed: 21308720]
  • Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006;38(6):652–8. OVID-Medline. Exclude: Candidate gene study. [PubMed: 16682969]
  • Andreassen CN, Alsner J. Genetic variants and normal tissue toxicity after radiotherapy: A systematic review. Radiother Oncol. 2009;92(3):299–309. OVID-Embase. Exclude: Study Design. [PubMed: 19683821]
  • Angele S, Falconer A, Edwards SM, et al. ATM polymorphisms as risk factors for prostate cancer development. Br J Canc. 2004;91(4):783–7. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC2364767] [PubMed: 15280931]
  • Anghel A, Narita D, Seclaman E, et al. Estrogen receptor alpha polymorphisms and the risk of malignancies. Pathol Oncol Res. 2010;16(4):485–96. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 20383761]
  • Arslan S, Pinarbasi H, Silig Y. Myeloperoxidase G-463A polymorphism and risk of lung and prostate cancer in a Turkish population. Mol Med Rep. 2011;4(1):87–92. OVID-Medline. Exclude: Test not commercially available. [PubMed: 21461569]
  • Arsova-Sarafinovska Z, Matevska N, Petrovski D, et al. Manganese superoxide dismutase (MnSOD) genetic polymorphism is associated with risk of early-onset prostate cancer. Cell Biochem Funct. 2008;26(7):771–7. OVID-Embase. Exclude: Test not commercially available. [PubMed: 18646267]
  • Ashtiani ZO, Hasheminasab SM, Ayati M, et al. Are GSTM1, GSTT1 and CAG repeat length of androgen receptor gene polymorphisms associated with risk of prostate cancer in Iranian patients? Pathol Oncol Res. 2011;17(2):269–75. OVID-Medline. Exclude: Candidate gene study. [PubMed: 21089003]
  • Assie G, LaFramboise T, Platzer P, et al. Frequency of germline genomic homozygosity associated with cancer cases. JAMA. 2008;299(12):1437–45. OVID-Medline. Exclude: No test panel of human SNP. [PubMed: 18364486]
  • Azria D, Ozsahin M, Kramar A, et al. Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Canc Res. 2008;14(19):6284–8. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC2771757] [PubMed: 18829510]
  • Bachmann N, Hoegel J, Haeusler J, et al. Mutation screen and association study of EZH2 as a susceptibility gene for aggressive prostate cancer. Prostate. 2005;65(3):252–9. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16015586]
  • Baffoe-Bonnie AB, Smith JR, Stephan DA, et al. A major locus for hereditary prostate cancer in Finland: Localization by linkage disequilibrium of a haplotype in the HPCX region. Hum Genet. 2005;117(4):307–16. OVID-Medline. Exclude: Test not commercially available. [PubMed: 15906096]
  • Balistreri CR, Caruso C, Carruba G, et al. A pilot study on prostate cancer risk and pro-inflammatory genotypes: Pathophysiology and therapeutic implications. Curr Pharmaceut Des. 2010;16(6):718–24. OVID-Embase. Exclude: Test not commercially available. [PubMed: 20388081]
  • Balistreri CR, Caruso C, Carruba G, et al. Genotyping of sex hormone-related pathways in benign and malignant human prostate tissues: Data of a preliminary study. OMICS. 2011;15(6):369–74. OVID-Embase. Exclude: Test not commercially available. [PubMed: 21348640]
  • Balistreri CR, Caruso C, Listi F, et al. LPS-mediated production of pro/anti-inflammatory cytokines and eicosanoids in whole blood samples: Biological effects of +896A/G TLR4 polymorphism in a Sicilian population of healthy subjects. Mech Ageing Dev. 2011;132(3):86–92. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 21238472]
  • Bao BY, Pao JB, Lin VC, et al. Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease. Clinica Chimica Acta. 2010;411(17-18):1232–7. OVID-Embase. Exclude: Doesn't include test panel. [PubMed: 20450899]
  • Bao BY, Pao JB, Huang CN, et al. Polymorphisms inside MicroRNAs and MicroRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clin Canc Res. 2011;17(4):928–36. OVID-Embase. Exclude: Doesn't include test panel. [PubMed: 21149617]
  • Bao S, Yang W, Zhou S, et al. Relationship between single nucleotide polymorphisms in -174G/C and -634C/G promoter region of interleukin-6 and prostate cancer. J Huazhong U Sci Tech. 2008;(6):693–6. Medical. OVID-Medline. Exclude: Test not commercially available. [PubMed: 19107369]
  • Beebe-Dimmer JL, Levin AM, Ray AM, et al. Chromosome 8q24 markers: Risk of early-onset and familial prostate cancer. Int J Canc. 2008;122(12):2876–9. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2695763] [PubMed: 18360876]
  • Beebe-Dimmer JL, Zuhlke KA, Ray AM, et al. Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans. Prostate Canc P Dis. 2010;13(4):362–8. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2978765] [PubMed: 20697428]
  • Beebe-Dimmer JL, Lange LA, Cain JE, et al. Polymorphisms in the prostate-specific antigen gene promoter do not predict serum prostate-specific antigen levels in African-American men. Prostate Canc P Dis. 2006;9(1):50–5. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16247489]
  • Benn M, Tybjaerg-Hansen A, Stender S, et al. Low-density lipoprotein cholesterol and the risk of cancer: A mendelian randomization study. J Natl Canc Inst. 2011;103(6):508–19. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 21285406]
  • Berndt SI, Sampson J, Yeager M, et al. Large-scale fine mapping of the HNF1B locus and prostate cancer risk. Hum Mol Genet. 2011;20(16):3322–9. OVID-Embase. Exclude: SNP assessment in single gene. [PMC free article: PMC3140817] [PubMed: 21576123]
  • Berndt SI, Chatterjee N, Huang WY, et al. Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Canc Epidemiol Biomarkers Prev. 2007;16(1):165–8. OVID-Embase. Exclude: Test not commercially available. [PubMed: 17220347]
  • Bessarabova M, Pustovalova O, Shi W, et al. Functional synergies yet distinct modulators affected by genetic alterations in common human cancers. Canc Res. 2011;71(10):3471–81. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 21398405]
  • Beuten J, Gelfond JA, Martinez-Fierro ML, et al. Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men. Carcinogenesis. 2009;30(8):1372–9. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2718079] [PubMed: 19528667]
  • Beuten J, Gelfond JA, Byrne JJ, et al. CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians. Carcinogenesis. 2008;29(9):1751–7. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2527647] [PubMed: 18544568]
  • Beuten J, Garcia D, Brand TC, et al. Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis. J Urol. 2009;182(4):1614–20. OVID-Medline. Exclude: Test not commercially available. [PubMed: 19683737]
  • Beuten J, Gelfond JA, Franke JL, et al. Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. Canc Epidemiol Biomarkers Prev. 2010;19(2):588–99. OVID-Medline. Exclude: Candidate gene study. [PubMed: 20086112]
  • Bignell G, Smith R, Hunter C, et al. Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adolescents and adults. Gene Chromosome Canc. 2006;45(1):42–6. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 16175573]
  • Bochum S, Paiss T, Vogel W, et al. Confirmation of the prostate cancer susceptibility locus HPCX in a set of 104 German prostate cancer families. Prostate. 2002;52(1):12–9. OVID-Embase. Exclude: Test not commercially available. [PubMed: 11992616]
  • Bock CH, Schwartz AG, Ruterbusch JJ, et al. Results from a prostate cancer admixture mapping study in African-American men. Hum Genet. 2009;126(5):637–42. OVID-Medline. Exclude: GWA study. [PMC free article: PMC2975267] [PubMed: 19568772]
  • Bonilla C, Mason T, Long L, et al. E-cadherin polymorphisms and haplotypes influence risk for prostate cancer. Prostate. 2006;66(5):546–56. OVID-Embase. Exclude: Test not commercially available. [PubMed: 16372334]
  • Bonilla C, Hooker S, Mason T, et al. Prostate cancer susceptibility loci identified on chromosome 12 in African Americans. PLoS One. 2011;6(2):e16044. OVID-Embase. Exclude: Candidate gene study. [PMC free article: PMC3040176] [PubMed: 21358824]
  • Brajuskovic G, Mircetic J, Savic PD, et al. Analysis of five single nucleotide polymorphisms at locus 8q24 associated with prostate cancer in Serbian population. Virchows Archiv; Conference: 23rd European Congress of Pathology: Pathology - Diagnostic, Prognostic, Predictive; Helsinki Finland. 2011. p. S319. OVID-Embase. Exclude: Study Design.
  • Brand TC, Bermejo C, Canby-Hagino E, et al. Association of polymorphisms in TGFB1 and prostate cancer prognosis. J Urol. 2008;179(2):754–8. OVID-Medline. Exclude: Test not commercially available. [PubMed: 18082198]
  • Breyer JP, McReynolds KM, Yaspan BL, et al. Genetic variants and prostate cancer risk: Candidate replication and exploration of viral restriction genes. Canc Epidemiol Biomarkers Prev. 2009;18(7):2137–44. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2813685] [PubMed: 19567509]
  • Brooks J. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Urol Oncol. 2008;26(5):569–70. OVID-Embase. Exclude: Study Design.
  • Brooks J. Multiple loci identified in a genome-wide association study of prostate cancer. Urol Oncol. 2008;26(5):571. OVID-Embase. Exclude: Study Design.
  • Brooks J. Multiple newly identified loci associated with prostate cancer susceptibility. Urol Oncol. 2008;26(5):570. OVID-Embase. Exclude: Study Design.
  • Burmester JK, Suarez BK, Lin JH, et al. Analysis of candidate genes for prostate cancer. Hum Hered. 2004;57(4):172–8. OVID-Medline. Exclude: Test not commercially available. [PubMed: 15583422]
  • Burri RJ, Stock RG, Cesaretti JA, et al. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res. 2008;170(1):49–59. OVID-Medline. Exclude: Candidate gene study. [PubMed: 18582155]
  • Cai D, Ning L, Pan C, et al. Association of polymorphisms in folate metabolic genes and prostate cancer risk: A case-control study in a Chinese population. J Genet. 2010;89(2):263–7. OVID-Medline. Exclude: Test not commercially available. [PubMed: 20861582]
  • Camp NJ, Tavtigian SV. Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer. Am J Hum Genet. 2002;71(6):1475–8. OVID-Medline. Exclude: Study Design. [PMC free article: PMC378598] [PubMed: 12515253]
  • Camp NJ, Farnham JM, Wong J, et al. Replication of the 10q11 and Xp11 prostate cancer risk variants: Results from a Utah pedigree-based study. Canc Epidemiol Biomarkers Prev. 2009;18(4):1290–4. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2697376] [PubMed: 19336566]
  • Campa D, Husing A, Chang-Claude J, et al. Genetic variability of the fatty acid synthase pathway is not associated with prostate cancer risk in the European Prospective Investigation on Cancer (EPIC) Eur J Canc. 2011;47(3):420–7. OVID-Medline. Exclude: Candidate gene study. [PubMed: 20965718]
  • Campa D, Husing A, Dostal L, et al. Genetic variability of the forkhead box O3 and prostate cancer risk in the European Prospective Investigation on Cancer. Oncol Rep. 2011;26(4):979–86. OVID-Embase. Exclude: Test not commercially available. [PubMed: 21725602]
  • Campa D, Husing A, Stein A, et al. Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC) PLoS One. 2011;6(2):e16914. OVID-Embase. Exclude: Candidate gene study. [PMC free article: PMC3044148] [PubMed: 21373201]
  • Campa D, Kaaks R, Le ML, et al. Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. J Natl Canc Inst. 2011;103(16):1252–63. OVID-Embase. Exclude: Not about prostate cancer. [PMC free article: PMC3156803] [PubMed: 21791674]
  • Cancel-Tassin G, Latil A, Valeri A, et al. No evidence of linkage to HPC20 on chromosome 20q13 in hereditary prostate cancer. Int J Canc. 2001;93(3):455–6. OVID-Medline. Exclude: Study Design. [PubMed: 11433415]
  • Cancel-Tassin G, Latil A, Valeri A, et al. PCAP is the major known prostate cancer predisposing locus in families from south and west Europe. Eur J Hum Genet. 2001;9(2):135–42. OVID-Medline. Exclude: Test not commercially available. [PubMed: 11313747]
  • Canzian F, Cox DG, Setiawan VW, et al. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Hum Mol Genet. 2010;19(19):3873–84. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC2935856] [PubMed: 20634197]
  • Castro P, Creighton CJ, Ozen M, et al. Genomic profiling of prostate cancers from African American men. Neoplasia (New York) 2009;11(3):305–12. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2647733] [PubMed: 19242612]
  • Chae YK, Huang HY, Strickland P, et al. Genetic polymorphisms of estrogen receptors alpha and beta and the risk of developing prostate cancer. PLoS One. 2009;4(8):e6523. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2715882] [PubMed: 19654868]
  • Chang BL, Zheng SL, Isaacs SD, et al. A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Canc Res. 2004;64(6):1997–9. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 15026335]
  • Chang BL, Zheng SL, Isaacs SD, et al. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer. Prostate. 2003;56(1):37–44. OVID-Medline. Exclude: Test not commercially available. [PubMed: 12746845]
  • Chang BL, Cramer SD, Wiklund F, et al. Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet. 2009;18(7):1368–75. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC2722195] [PubMed: 19153072]
  • Chang BL, Liu W, Sun J, et al. Integration of somatic deletion analysis of prostate cancers and germline linkage analysis of prostate cancer families reveals two small consensus regions for prostate cancer genes at 8p. Canc Res. 2007;67(9):4098–103. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 17483320]
  • Chang BL, Zheng SL, Hawkins GA, et al. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Canc Res. 2002;62(6):1784–9. OVID-Medline. Exclude: Test not commercially available. [PubMed: 11912155]
  • Chang BL, Zheng SL, Isaacs SD, et al. Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Int J Canc. 2003;106(3):375–8. OVID-Medline. Exclude: SNP assessment in single gene. [PubMed: 12845676]
  • Chang BL, Zheng SL, Isaacs SD, et al. Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br J Canc. 2003;89(8):1524–9. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC2394327] [PubMed: 14562027]
  • Chang CH, Chiu CF, Wu HC, et al. Significant association of XRCC4 single nucleotide polymorphisms with prostate cancer susceptibility in Taiwanese males. Mol Med Rep. 2008;1(4):525–30. OVID-Embase. Exclude: Test not commercially available. [PubMed: 21479444]
  • Chaturvedi AK, Caporaso NE, Katki HA, et al. C-reactive protein and risk of lung cancer. J Clin Oncol. 2010;28(16):2719–26. OVID-Embase. Exclude: Not about prostate cancer. [PMC free article: PMC2881850] [PubMed: 20421535]
  • Chau CH, Permenter MG, Steinberg SM, et al. Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. Canc Biol Ther. 2005;4(11):1222–5. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16205110]
  • Chavan SV, Maitra A, Roy N, et al. Genetic variants in the distal enhancer region of the PSA gene and their implication in the occurrence of advanced prostate cancer. Mol Med Rep. 2010;3(5):837–43. OVID-Embase. Exclude: SNP assessment in single gene. [PubMed: 21472323]
  • Chen H, Hernandez W, Shriver MD, et al. ICAM gene cluster SNPs and prostate cancer risk in African Americans. Hum Genet. 2006;120(1):69–76. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16733712]
  • Chen J, Rodriguez C. Conditional likelihood methods for haplotype-based association analysis using matched case-control data. Biometrics. 2007;63(4):1099–107. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 18078481]
  • Chen M, Huang YC, Yang S, et al. Association between the prostate-specific antigen gene and the risk of prostate cancer in a Taiwanese population. Urol Sci. 2011;22(1):28–31. OVID-Embase. Exclude: Test not commercially available.
  • Chen YC, Giovannucci E, Kraft P, et al. Association between genetic polymorphisms of macrophage scavenger receptor 1 gene and risk of prostate cancer in the health professionals follow-up study. Canc Epidemiol Biomarkers Prev. 2008;17(4):1001–3. OVID-Medline. Exclude: SNP assessment in single gene. [PubMed: 18398045]
  • Chen YC, Giovannucci E, Kraft P, et al. Association between Toll-like receptor gene cluster (TLR6, TLR1, and TLR10) and prostate cancer. Canc Epidemiol Biomarkers Prev. 2007;16(10):1982–9. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 17932345]
  • Chen YC, Giovannucci E, Kraft P, et al. Sequence variants of elaC homolog 2 (Escherichia coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study. Carcinogenesis. 2008;29(5):999–1004. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC2902389] [PubMed: 18375959]
  • Chen YC, Kraft P, Bretsky P, et al. Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Canc Epidemiol Biomarkers Prev. 2007;16(10):1973–81. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17932344]
  • Chen YC, Giovannucci E, Lazarus R, et al. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Canc Res. 2005;65(24):11771–8. OVID-Medline. Exclude: SNP assessment in single gene. [PubMed: 16357190]
  • Cheng I, Plummer SJ, Jorgenson E, et al. 8q24 and prostate cancer: Association with advanced disease and meta-analysis. Eur J Hum Genet. 2008;16(4):496–505. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2819154] [PubMed: 18231127]
  • Cheng I, Stram DO, Penney KL, et al. Common genetic variation in IGF1 and prostate cancer risk in the multiethnic cohort. J Natl Canc Inst. 2006;98(2):123–34. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16418515]
  • Cheng I, Liu X, Plummer SJ, et al. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Canc. 2007;97(4):557–61. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2360347] [PubMed: 17609663]
  • Cheng I, Penney KL, Stram DO, et al. Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: The multiethnic cohort. Canc Epidemiol Biomarkers Prev. 2006;15(10):1993–7. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17035411]
  • Cheng I, Krumroy LM, Plummer SJ, et al. MIC1 and IL1RN genetic variation and advanced prostate cancer risk. Canc Epidemiol Biomarkers Prev. 2007;16(6):1309–11. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17548705]
  • Cheng I, Plummer SJ, Neslund-Dudas C, et al. Prostate cancer susceptibility variants confer increased risk of disease progression. Canc Epidemiol Biomarkers Prev. 2010;19(9):2124–32. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2950095] [PubMed: 20651075]
  • Cheng I, Plummer SJ, Casey G, et al. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Canc Epidemiol Biomarkers Prev. 2007;16(2):352–5. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17301271]
  • Cheng Y, Kim JW, Liu W, et al. Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer. Prostate. 2009;69(3):327–35. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC2795318] [PubMed: 19035483]
  • Chiang CH, Chen KK, Chang LS, et al. The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer. J Urol. 2004;171(4):1529–32. OVID-Embase. Exclude: Test not commercially available. [PubMed: 15017213]
  • Chu H, Wang M, Shi D, et al. Hsa-miR-196a2 Rs11614913 polymorphism contributes to cancer susceptibility: Evidence from 15 case-control studies. PLoS One. 2011;6(3):e18108. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC3069063] [PubMed: 21483822]
  • Chu LW, Meyer TE, Li Q, et al. Association between genetic variants in the 8q24 cancer risk regions and circulating levels of androgens and sex hormone-binding globulin. Canc Epidemiol Biomarkers Prev. 2010;19(7):1848–54. OVID-Embase. Exclude: Study design. [PMC free article: PMC2901401] [PubMed: 20551303]
  • Chu LW, Zhu Y, Yu K, et al. Variants in circadian genes and prostate cancer risk: A population-based study in China. Prostate Canc P Dis. 2008;11(4):342–8. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17984998]
  • Chung CC, Ciampa J, Yeager M, et al. Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. Hum Mol Genet. 2011;20(14):2869–78. OVID-Embase. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3118760] [PubMed: 21531787]
  • Chung S, Nakagawa H, Uemura M, et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Canc Sci. 2011;102(1):245–52. OVID-Medline. Exclude: Candidate gene study. [PubMed: 20874843]
  • Cicek MS, Liu X, Casey G, et al. Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Canc Epidemiol Biomarkers Prev. 2005;14(9):2173–7. OVID-Embase. Exclude: Test not commercially available. [PubMed: 16172228]
  • Claiborne SJ, Bamshad M. Population choice as a consideration for genetic analysis study design. Cold Spring Harbor Protocols. 2011;6(8):917–22. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 21807860]
  • Collin SM, Metcalfe C, Zuccolo L, et al. Association of folate-pathway gene polymorphisms with the risk of prostate cancer: A population-based nested case-control study, systematic review, and meta-analysis. Canc Epidemiol Biomarkers Prev. 2009;18(9):2528–39. OVID-Embase. Exclude: Study Design. [PubMed: 19706844]
  • Collin SM, Metcalfe C, Refsum H, et al. Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with prostate-specific antigen velocity in men with localized prostate cancer. Canc Epidemiol Biomarkers Prev. 2010;19(11):2833–8. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 20852008]
  • Cooper ML, Adami HO, Gronberg H, et al. Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk. Canc Res. 2008;68(24):10171–7. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2800981] [PubMed: 19074884]
  • Cornu JN, Drouin S, Cancel-Tassin G, et al. Impact of genotyping on outcome of prostatic biopsies: A multicenter prospective study. Mol Med. 2011;17(5-6):473–7. OVID-Embase. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3105129] [PubMed: 21308149]
  • Costa S, Pinto D, Morais A, et al. Acetylation genotype and the genetic susceptibility to prostate cancer in a Southern European population. Prostate. 2005;64(3):246–52. OVID-Embase. Exclude: Test not commercially available. [PubMed: 15717312]
  • Cramer SD, Chang BL, Rao A, et al. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Canc Inst. 2003;95(14):1044–53. OVID-Medline. Exclude: Candidate gene study. [PubMed: 12865450]
  • Cramer SD, Sun J, Zheng SL, et al. Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer. Canc Epidemiol Biomarkers Prev. 2008;17(9):2451–7. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC4114034] [PubMed: 18768516]
  • Cunningham JM, Hebbring SJ, McDonnell SK, et al. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Canc Epidemiol Biomarkers Prev. 2007;16(5):969–78. OVID-Embase. Exclude: Test not commercially available. [PubMed: 17507624]
  • Cussenot O, Azzouzi AR, Bantsimba-Malanda G, et al. Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer. Clin Canc Res. 2008;14(17):5635–9. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 18765558]
  • Cybulski C, Gorski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004;75(6):1131–5. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC1182149] [PubMed: 15492928]
  • Cybulski C, Gorski B, Debniak T, et al. NBS1 is a prostate cancer susceptibility gene. Canc Res. 2004;64(4):1215–9. OVID-Embase. Exclude: Test not commercially available. [PubMed: 14973119]
  • Damaraju S, Murray D, Dufour J, et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Canc Res. 2006;12(8):2545–54. OVID-Medline. Exclude: Candidate gene study. [PubMed: 16638864]
  • Danforth KN, Hayes RB, Rodriguez C, et al. Polymorphic variants in PTGS2 and prostate cancer risk: Results from two large nested case-control studies. Carcinogenesis. 2008;29(3):568–72. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17999989]
  • Danforth KN, Rodriguez C, Hayes RB, et al. TNF polymorphisms and prostate cancer risk. Prostate. 2008;68(4):400–7. OVID-Medline. Exclude: Test not commercially available. [PubMed: 18196539]
  • Daugherty SE, Shugart YY, Platz EA, et al. Polymorphic variants in alpha-methylacyl-CoA racemase and prostate cancer. Prostate. 2007;67(14):1487–97. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17680641]
  • De Alencar SA, Lopes JCD. A comprehensive in silico analysis of the functional and structural impact of SNPs in the IGF1R gene. J Biomed Biotechnol. 2010. Article Number: 715139.: OVID-Embase. Exclude: Not about prostate cancer. [PMC free article: PMC2896858] [PubMed: 20625407]
  • Deeken JF, Cormier T, Price DK, et al. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J. 2010;10(3):191–9. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 20038957]
  • Ding Y, Larson G, Rivas G, et al. Strong signature of natural selection within an FHIT intron implicated in prostate cancer risk. PLoS One. 2008;3(10):e3533. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC2568805] [PubMed: 18953408]
  • Dong LM, Potter JD, White E, et al. Genetic susceptibility to cancer: The role of polymorphisms in candidate genes. JAMA. 2008;299(20):2423–36. OVID-Embase. Exclude: Study Design. [PMC free article: PMC2772197] [PubMed: 18505952]
  • Dos Reis ST, Villanova FE, De Andrade PM, et al. Polymorphisms of the matrix metalloproteinases associated with prostate cancer. Mol Med Rep. 2008;1(4):517–20. OVID-Embase. Exclude: Test not commercially available. [PubMed: 21479442]
  • Dos Santos RM, De Jesus CMN, Trindade Filho JCS, et al. PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy. DNA Cell Biol. 2008;27(9):497–503. OVID-Embase. Exclude: Test not commercially available. [PubMed: 18491956]
  • dos SA, Ribeiro ML, Mesquita JC, et al. No association of the 5' promoter region polymorphism of CYP17 gene with prostate cancer risk. Prostate Canc P Dis. 2002;5(1):28–31. OVID-Embase. Exclude: Test not commercially available. [PubMed: 15195127]
  • Dossus L, Kaaks R, Canzian F, et al. PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: Results from the Breast and Prostate Cancer Cohort Consortium (BPC3) Carcinogenesis. 2010;31(3):455–61. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2832545] [PubMed: 19965896]
  • Douglas JA, Levin AM, Zuhlke KA, et al. Common variation in the BRCA1 gene and prostate cancer risk. Canc Epidemiol Biomarkers Prev. 2007;16(7):1510–6. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC3082399] [PubMed: 17585057]
  • Douglas JA, Zuhlke KA, Beebe-Dimmer J, et al. Identifying susceptibility genes for prostate cancer: A family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Canc Epidemiol Biomarkers Prev. 2005;14(8):2035–9. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16103457]
  • Drakoulis N, Papanikolopoulou A, Landt O, et al. Association study of rs6983267 at 8q24 with prostate cancer in the Greek population. Eur J Oncol Pharm. 2010;4(2):12–3. OVID-Embase. Exclude: No test panel of human SNP.
  • Duggan D, Zheng SL, Knowlton M, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Canc Inst. 2007;99(24):1836–44. OVID-Medline. Exclude: GWA study. [PubMed: 18073375]
  • Eder T, Mayer R, Langsenlehner U, et al. Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: A population-based study. Eur J Canc. 2007;43(3):472–5. OVID-Embase. Exclude: Test not commercially available. [PubMed: 17182240]
  • Edwards SM, Kote-Jarai Z, Meitz J, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet. 2003;72(1):1–12. OVID-Medline. Exclude: Study design. [PMC free article: PMC420008] [PubMed: 12474142]
  • Eeles RA, Kote-Jarai Z, Al Olama AA, et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 2009;41(10):1116–21. OVID-Medline. Exclude: GWA study. [PMC free article: PMC2846760] [PubMed: 19767753]
  • Ekhart C, Rodenhuis S, Smits PH, et al. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenetics & Genomics. 2008;18(11):1009–15. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 18854779]
  • Eklund CM, Tammela TL, Schleutker J, et al. C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk. Br J Canc. 2009;100(12):1846–51. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2714238] [PubMed: 19436291]
  • Eriksson AL, Lorentzon M, Vandenput L, et al. Genetic variations in sex steroid-related genes as predictors of serum estrogen levels in men. J Clin Endocrinol Metabol. 2009;94(3):1033–41. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC2681277] [PubMed: 19116238]
  • Eroglu A, Ozturk A, Cam R, et al. Intron F G79A polymorphism of the protein Z gene in cancer patients with and without thrombosis. J Thromb Thrombolysis. 2009;27(2):204–6. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 18246466]
  • Eroglu A, Ulu A, Cam R, et al. Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients. J Buon. 2007;12(1):135–6. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 17436417]
  • Eroglu A, Gulec S, Akar N. Vascular endothelial growth factor C936T polymorphism in cancer patients with thrombosis. Am J Hematol. 2007;82(2):174. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 16917915]
  • Fall K, Stark JR, Mucci LA, et al. No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk. Prostate. 2008;68(13):1416–20. OVID-Medline. Exclude: No test panel of human SNP. [PMC free article: PMC2958090] [PubMed: 18615538]
  • Fang S, Krahe R, Lozano G, et al. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One. 2010;5(5):e10813. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC2877078] [PubMed: 20520810]
  • Faupel-Badger JM, Kidd LC, Albanes D, et al. Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Canc Causes Contr. 2008;19(2):119–24. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17999153]
  • Feik E, Baierl A, Madersbacher S, et al. Common genetic polymorphisms of AURKA and prostate cancer risk. Canc Causes Contr. 2009;20(2):147–52. OVID-Medline. Exclude: Test not commercially available. [PubMed: 18802780]
  • Fernandez P, de Beer PM, van der Merwe L, et al. COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men. Carcinogenesis. 2008;29(12):2347–50. OVID-Medline. Exclude: SNP assessment in single gene. [PubMed: 18974063]
  • Fernandez P, de Beer PD, van der Merwe LD, et al. Genetic variations in androgen metabolism genes and associations with prostate cancer in South African men. S Afr Med J. 2010;100(11):741–5. OVID-Embase. Exclude: Test not commercially available. [PubMed: 21081028]
  • Ferreira PM, Medeiros R, Vasconcelos A, et al. Association between CYP2E1 polymorphisms and susceptibility to prostate cancer. Eur J Canc Prev. 2003;12(3):205–11. OVID-Medline. Exclude: Test not commercially available. [PubMed: 12771559]
  • Fesinmeyer MD, Kwon EM, Fu R, et al. Genetic variation in RNASEL and risk for prostate cancer in a population-based case-control study. Prostate. 2011;71(14):1538–47. OVID-Embase. Exclude: SNP assessment in single gene. [PMC free article: PMC3130811] [PubMed: 21360564]
  • Figueroa JD, Malats N, Garcia-Closas M, et al. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis. 2008;29(10):1955–62. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC2556968] [PubMed: 18632753]
  • Fitzgerald LM, Kwon EM, Koopmeiners JS, et al. Analysis of recently identified prostate cancer susceptibility loci in a population-based study: Associations with family history and clinical features. Clin Canc Res. 2009;15(9):3231–7. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2707085] [PubMed: 19366831]
  • Fitzgerald LM, Karlins E, Karyadi DM, et al. Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. Prostate Canc P Dis. 2009;12(2):192–7. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC2790323] [PubMed: 18762813]
  • Fitzgerald LM, Agalliu I, Johnson K, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: Results from a population-based study of prostate cancer. BMC Canc. 2008;8:230. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2519091] [PubMed: 18694509]
  • Fitzgerald LM, McDonnell SK, Carlson EE, et al. Genome-wide linkage analyses of hereditary prostate cancer families with colon cancer provide further evidence for a susceptibility locus on 15q11-q14. Eur J Hum Genet. 2010;18(10):1141–7. OVID-Medline. Exclude: Study Design. [PMC free article: PMC2921483] [PubMed: 20407467]
  • Fitzgerald LM, Patterson B, Thomson R, et al. Identification of a prostate cancer susceptibility gene on chromosome 5p13q12 associated with risk of both familial and sporadic disease. Eur J Hum Genet. 2009;17(3):368–77. OVID-Medline. Exclude: GWA study. [PMC free article: PMC2986161] [PubMed: 18830231]
  • Fitzgerald LM, Thomson R, Polanowski A, et al. Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk: A replication study in an ethnically homogeneous population. Prostate. 2008;68(13):1373–9. OVID-Medline. Exclude: Test not commercially available. [PubMed: 18537123]
  • Foley R, Marignol L, Thomas AZ, et al. The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers. Canc Biol Ther. 2009;8(2):118–24. OVID-Embase. Exclude: Test not commercially available. [PubMed: 19106642]
  • Folsom AR, Pankow JS, Peacock JM, et al. Variation in TCF7L2 and increased risk of colon cancer: The Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. 2008;31(5):905–9. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2577771] [PubMed: 18268068]
  • Forszt P, Pilecka A, Malodobra M, et al. Single-nucleotide polymorphism association study of VDR and CDH1 genes and the risk of prostate cancer. Adv Clin Exp Med. 2009;18(3):215–20. OVID-Embase. Exclude: Candidate gene study.
  • Fradet V, Cheng I, Casey G, et al. Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin Canc Res. 2009;15(7):2559–66. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC2749066] [PubMed: 19318492]
  • Fredriksson H, Ikonen T, Autio V, et al. Identification of germline MLH1 alterations in familial prostate cancer. Eur J Canc. 2006;42(16):2802–6. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16963262]
  • Freedman ML, Pearce CL, Penney KL, et al. Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. Am J Hum Genet. 2005;76(1):82–90. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC1196436] [PubMed: 15570555]
  • Friedrichsen DM, Stanford JL, Isaacs SD, et al. Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families. Proc Natl Acad Sci USA. 2004;101(7):1939–44. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC357031] [PubMed: 14769943]
  • Gallagher DJ, Vijai J, Cronin AM, et al. Susceptibility loci associated with prostate cancer progression and mortality. Clin Canc Res. 2010;16(10):2819–32. OVID-Medline. Exclude: Doesn't include test panel. [PMC free article: PMC3732009] [PubMed: 20460480]
  • Gao R, Price DK, Dahut WL, et al. Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer. Canc Biol Ther. 2010;10(1):13–8. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC3040830] [PubMed: 20495366]
  • Gardner ER, Ahlers CM, Shukla S, et al. Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. BJU Int. 2008;102(11):1694–9. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2605573] [PubMed: 18710444]
  • Gelmann EP, Steadman DJ, Ma J, et al. Occurrence of NKX3.1 C154T polymorphism in men with and without prostate cancer and studies of its effect on protein function. Canc Res. 2002;62(9):2654–9. OVID-Embase. Exclude: Test not commercially available. [PubMed: 11980664]
  • George GP, Gangwar R, Mandal RK, et al. Genetic variation in microRNA genes and prostate cancer risk in North Indian population. Mol Biol Rep. 2011;38(3):1609–15. OVID-Medline. Exclude: Test not commercially available. [PubMed: 20842445]
  • Ghoussaini M, Song H, Koessler T, et al. Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Canc Inst. 2008;100(13):962–6. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2902819] [PubMed: 18577746]
  • Giri VN, Ruth K, Hughes L, et al. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: Effect of TMPRSS2 Met160Val. BJU Int. 2011;107(3):466–70. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC3052292] [PubMed: 20735386]
  • Glinsky GV. An SNP-guided microRNA map of fifteen common human disorders identifies a consensus disease phenocode aiming at principal components of the nuclear import pathway. Cell Cycle. 2008;7(16):2570–83. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 18719369]
  • Glinsky GV. Integration of HapMap-based SNP pattern analysis and gene expression profiling reveals common SNP profiles for cancer therapy outcome predictor genes. Cell Cycle. 2006;5(22):2613–25. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 17172834]
  • Glinsky GV. SNP-guided microRNA maps (MirMaps) of 16 common human disorders identify a clinically accessible therapy reversing transcriptional aberrations of nuclear import and inflammasome pathways. Cell Cycle. 2008;7(22):3564–76. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 19001869]
  • Grindedal EM, Moller P, Eeles R, et al. Germ-line mutations in mismatch repair genes associated with prostate cancer. Canc Epidemiol Biomarkers Prev. 2009;18(9):2460–7. OVID-Medline. Exclude: No test panel of human SNP. [PubMed: 19723918]
  • Gu F, Schumacher FR, Canzian F, et al. Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. Canc Epidemiol Biomarkers Prev. 2010;19(11):2877–87. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2989404] [PubMed: 20810604]
  • Gudmundsson J, Sulem P, Rafnar T, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet. 2008;40(3):281–3. OVID-Medline. Exclude: GWA study. [PMC free article: PMC3598012] [PubMed: 18264098]
  • Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet. 2009;41(10):1122–6. OVID-Medline. Exclude: GWA study. [PMC free article: PMC3562712] [PubMed: 19767754]
  • Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007;39(5):631–7. OVID-Medline. Exclude: GWA study. [PubMed: 17401366]
  • Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 2007;39(8):977–83. OVID-Medline. Exclude: GWA study. [PubMed: 17603485]
  • Gunes S, Bagci H, Sarikaya S, et al. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia. DNA Cell Biol. 2007;26(12):873–8. OVID-Embase. Exclude: Test not commercially available. [PubMed: 17961073]
  • Habuchi T, Liqing Z, Suzuki T, et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Canc Res. 2000;60(20):5710–3. OVID-Medline. Exclude: Test not commercially available. [PubMed: 11059764]
  • Haeusler J, Hoegel J, Bachmann N, et al. Association of a CAV-1 haplotype to familial aggressive prostate cancer. Prostate. 2005;65(2):171–7. OVID-Medline. Exclude: SNP assessment in single gene. [PubMed: 15948133]
  • Hahn NM, Zon RT, Yu M, et al. A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. Ann Oncol. 2009;20(12):1971–6. OVID-Embase. Exclude: Doesn't include test panel. [PubMed: 19605506]
  • Haiman CA, Chen GK, Blot WJ, et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet. 2011;7(5):e1001387. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3102736] [PubMed: 21637779]
  • Haiman CA, Stram DO, Cheng I, et al. Common genetic variation at PTEN and risk of sporadic breast and prostate cancer. Canc Epidemiol Biomarkers Prev. 2006;15(5):1021–5. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16702386]
  • Haiman CA, Patterson N, Freedman ML, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet. 2007;39(5):638–44. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2638766] [PubMed: 17401364]
  • Hajdinjak T, Toplak N. E-Cadherin polymorphism - 160 C/A and prostate cancer. Int J Canc. 2004;109(3):480–1. OVID-Embase. Exclude: Test not commercially available. [PubMed: 14961592]
  • Hajdinjak T, Zagradisnik B. Prostate cancer and polymorphism D85Y in gene for dihydrotestosterone degrading enzyme UGT2B15: Frequency of DD homozygotes increases with Gleason score. Prostate. 2004;59(4):436–9. OVID-Embase. Exclude: Test not commercially available. [PubMed: 15065092]
  • Hamada A, Sissung T, Price DK, et al. Effect of SLC01B3 haplotype on testosterone transport and clinical outcome in Caucasian patients with androgen-independent prostatic cancer. Clin Canc Res. 2008;14(11):3312–8. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC2701141] [PubMed: 18519758]
  • Hamano T, Matsui H, Sekine Y, et al. Association of SNP rs1447295 and microsatellite marker DG8S737 with familial prostate cancer and high grade disease. J Urol. 2010;184(2):738–42. OVID-Medline. Exclude: Test not commercially available. [PubMed: 20639049]
  • Hampel H, Sweet K, Westman JA, et al. Referral for cancer genetics consultation: A review and compilation of risk assessment criteria. J Med Genet. 2004;41(2):81–91. OVID-Medline. Exclude: Study Design. [PMC free article: PMC1735676] [PubMed: 14757853]
  • Havranek E, Howell WM, Fussell HM, et al. An interleukin-10 promoter polymorphism may influence tumor development in renal cell carcinoma. J Urol. 2005;173(3):709–12. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 15711248]
  • Hawkins GA, Mychaleckyj JC, Zheng SL, et al. Germline sequence variants of the LZTS1 gene are associated with prostate cancer risk. Canc Genet Cytogenet. 2002;137(1):1–7. OVID-Medline. Exclude: Test not commercially available. [PubMed: 12377406]
  • Hawkins GA, Cramer SD, Zheng SL, et al. Sequence variants in the human 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) gene are not associated with prostate cancer risk. Prostate. 2002;53(3):175–8. OVID-Medline. Exclude: Test not commercially available. [PubMed: 12386916]
  • Hayashi T, Imai K, Morishita Y, et al. Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance. Canc Res. 2006;66(1):563–70. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 16397273]
  • Hayes VM, Severi G, Padilla EJ, et al. 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int J Canc. 2007;120(4):776–80. OVID-Embase. Exclude: SNP assessment in single gene. [PubMed: 17136762]
  • Hayes VM, Severi G, Southey MC, et al. Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival. Canc Epidemiol Biomarkers Prev. 2006;15(6):1223–5. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16775185]
  • Hayes VM, Severi G, Eggleton SA, et al. The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. Canc Epidemiol Biomarkers Prev. 2005;14(4):993–6. OVID-Medline. Exclude: Test not commercially available. [PubMed: 15824176]
  • Hedelin M, Chang ET, Wiklund F, et al. Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Canc. 2007;120(2):398–405. OVID-Medline. Exclude: SNP assessment in single gene. [PubMed: 17066444]
  • Hedelin M, Balter KA, Chang ET, et al. Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer. Prostate. 2006;66(14):1512–20. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16921512]
  • Heikkila K, Silander K, Salomaa V, et al. C-reactive protein-associated genetic variants and cancer risk: Findings from FINRISK 1992, FINRISK 1997 and Health 2000 studies. Eur J Canc. 2011;47(3):404–12. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 20727736]
  • Hein DW, Leff MA, Ishibe N, et al. Association of prostate cancer with rapid N-acetyltransferase 1 (NAT1*10) in combination with slow N-acetyltransferase 2 acetylator genotypes in a pilot case-control study. Environ Mol Mutagen. 2002;40(3):161–7. OVID-Medline. Exclude: Test not commercially available. [PubMed: 12355549]
  • Helfand BT, McGuire BB, Hu Q, et al. Genetic risk alleles can predict active surveillance failures. J Urol; Conference: Annual Meeting of the American Urological Association, AUA; Washington, DC United States. 2011. p. e932. OVID-Embase. Exclude: Study design.
  • Helfand BT, Loeb S, Kan D, et al. Number of prostate cancer risk alleles may identify possibly ‘insignificant’ disease. BJU Int. 2010;106(11):1602–6. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3072834] [PubMed: 20590552]
  • Helfand BT, Loeb S, Meeks JJ, et al. Pathological outcomes associated with the 17q prostate cancer risk variants. J Urol. 2009;181(6):2502–7. OVID-Embase. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3140699] [PubMed: 19371897]
  • Helfand BT, Loeb S, Cashy J, et al. Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles. J Urol. 2008;179(6):2197–202. OVID-Embase. Exclude: SNP assessment in single gene. [PubMed: 18423739]
  • Hendrickson WK, Flavin R, Kasperzyk JL, et al. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011;29(17):2378–85. OVID-Embase. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3107752] [PubMed: 21537045]
  • Henningson M, Hietala M, Torngren T, et al. IGF1 htSNPs in relation to IGF-1 levels in young women from high-risk breast cancer families: Implications for early-onset breast cancer. Fam Canc. 2011;10(2):173–85. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 21113804]
  • Hernandez-Saavedra D, McCord JM. Association of a new intronic polymorphism of the SOD2 gene (G1677T) with cancer. Cell Biochem Funct. 2009;27(4):223–7. OVID-Medline. Exclude: Test not commercially available. [PubMed: 19405048]
  • Hernandez J, Balic I, Johnson-Pais TL, et al. Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. J Urol. 2006;175(2):523–7. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16406987]
  • Hernandez S, De MS, Agell L, et al. FGFR3 mutations in prostate cancer: Association with low-grade tumors. Mod Pathol. 2009;22(6):848–56. OVID-Embase. Exclude: Study design. [PubMed: 19377444]
  • Hernandez W, Grenade C, Santos ER, et al. IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis. 2007;28(10):2154–9. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17724372]
  • Hirata H, Hinoda Y, Kikuno N, et al. Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J Urol. 2009;181(4):1907–12. OVID-Embase. Exclude: Test not commercially available. [PubMed: 19237173]
  • Hirata H, Hinoda Y, Kikuno N, et al. CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Canc Res. 2007;13(17):5056–62. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17785557]
  • Hirata H, Hinoda Y, Kawamoto K, et al. Mismatch repair gene MSH3 polymorphism is associated with the risk of sporadic prostate cancer. J Urol. 2008;179(5):2020–4. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC3940351] [PubMed: 18355840]
  • Hlinkova K, Babal P, Berzinec P, et al. Rapid and efficient detection of EGFR mutations in problematic cytologic specimens by high-resolution melting analysis. Mol Diagn Ther. 2011;15(1):21–9. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 21469767]
  • Ho CK, Anwar S, Nanda J, et al. FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men. Prostate Canc P Dis. 2010;13(1):94–6. OVID-Medline. Exclude: Test not commercially available. [PubMed: 19918264]
  • Hodgson ME, Poole C, Olshan AF, et al. Smoking and selected DNA repair gene polymorphisms in controls: Systematic review and meta-analysis. Canc Epidemiol Biomarkers Prev. 2010;19(12):3055–68. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC3108462] [PubMed: 20935063]
  • Holick CN, Stanford JL, Kwon EM, et al. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Canc Epidemiol Biomarkers Prev. 2007;16(10):1990–9. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 17932346]
  • Holt SK, Kwon EM, Lin DW, et al. Association of hepsin gene variants with prostate cancer risk and prognosis. Prostate. 2010;70(9):1012–9. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2875316] [PubMed: 20166135]
  • Holt SK, Karyadi DM, Kwon EM, et al. Association of megalin genetic polymorphisms with prostate cancer risk and prognosis. Clin Canc Res. 2008;14(12):3823–31. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2675883] [PubMed: 18559602]
  • Holt SK, Kwon EM, Koopmeiners JS, et al. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate. 2010;70(13):1448–60. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2927712] [PubMed: 20687218]
  • Holt SK, Kwon EM, Peters U, et al. Vitamin D pathway gene variants and prostate cancer risk. Canc Epidemiol Biomarkers Prev. 2009;18(6):1929–33. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2743676] [PubMed: 19454612]
  • Hooker S, Bonilla C, Akereyeni F, et al. NAT2 and NER genetic variants and sporadic prostate cancer susceptibility in African Americans. Prostate Canc P Dis. 2008;11(4):349–56. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 18026184]
  • Hooker S, Hernandez W, Chen H, et al. Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans. Prostate. 2010;70(3):270–5. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 19902474]
  • Horn H, Pott C, Kalla J, et al. A multiplex MALDI-TOF MS approach facilitates genotyping of DNA from formalin-fixed paraffin-embedded tumour specimens. Pharmacogenetics Genom. 2010;20(10):598–604. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 20802378]
  • Hsu FC, Sun J, Wiklund F, et al. A novel prostate cancer susceptibility locus at 19q13. Canc Res. 2009;69(7):2720–3. OVID-Medline. Exclude: GWA study. [PMC free article: PMC2803342] [PubMed: 19318570]
  • Huang SP, Ting WC, Chen LM, et al. Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy. Ann Surg Oncol. 2010;17(1):312–22. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 19777185]
  • Huang SP, Lan YH, Lu TL, et al. Clinical significance of runt-related transcription factor 1 polymorphism in prostate cancer. BJU Int. 2011;107(3):486–92. OVID-Medline. Exclude: SNP assessment in single gene. [PubMed: 20735389]
  • Huang SP, Huang LC, Ting WC, et al. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Canc Epidemiol Biomarkers Prev. 2009;18(11):3068–74. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 19900942]
  • Huse K, Taudien S, Groth M, et al. Genetic variants of the copy number polymorphic beta-defensin locus are associated with sporadic prostate cancer. Tumor Biol. 2008;29(2):83–92. OVID-Medline. Exclude: Test not commercially available. [PubMed: 18515986]
  • Ikonen T, Matikainen MP, Syrjakoski K, et al. BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland. J Med Genet. 2003;40(8):e98. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC1735545] [PubMed: 12920090]
  • Imai K, Kricka LJ, Fortina P. Concordance study of 3 direct-to-consumer genetic-testing services. Clin Chem. 2011;57(3):518–21. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 21159896]
  • Innocenti F, Cooper GM, Stanaway IB, et al. Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet. 2011;7(5):e1002078. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC3102751] [PubMed: 21637794]
  • Ishak MB, Giri VN. A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies. Canc Epidemiol Biomarkers Prev. 2011;20(8):1599–610. OVID-Embase. Exclude: Study Design. [PubMed: 21715604]
  • Iughetti P, Suzuki O, Godoi PHC, et al. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Canc Res. 2001;61(20):7375–8. OVID-Embase. Exclude: Test not commercially available. [PubMed: 11606364]
  • Jaboin JJ, Hwang M, Perez CA, et al. No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes. Urol Oncol-Semin O I. 2011;29(3):319–23. OVID-Embase. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3782416] [PubMed: 19523862]
  • Jaboin JJ, Hwang M, Lopater Z, et al. The matrix metalloproteinase-7 polymorphism rs10895304 is associated with increased recurrence risk in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011;79(5):1330–5. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC3782412] [PubMed: 20605361]
  • Jacobs EJ, Hsing AW, Bain EB, et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Canc Epidemiol Biomarkers Prev. 2008;17(4):972–7. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 18398039]
  • Jakobsson J, Karypidis H, Johansson JE, et al. A functional C-G polymorphism in the CYP7B1 promoter region and its different distribution in Orientals and Caucasians. Pharmacogenomics J. 2004;4(4):245–50. OVID-Medline. Exclude: Test not commercially available. [PubMed: 15007371]
  • Jakobsson J, Palonek E, Lorentzon M, et al. A novel polymorphism in the 17beta-hydroxysteroid dehydrogenase type 5 (aldo-keto reductase 1C3) gene is associated with lower serum testosterone levels in Caucasian men. Pharmacogenomics J. 2007;7(4):282–9. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 16983398]
  • Jesser C, Mucci L, Farmer D, et al. Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels. Br J Canc. 2008;99(10):1743–7. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC2584945] [PubMed: 18827812]
  • Jin G, Sun J, Liu W, et al. Genome-wide copy-number variation analysis identifies common genetic variants at 20p13 associated with aggressiveness of prostate cancer. Carcinogenesis. 2011;32(7):1057–62. OVID-Medline. Exclude: Study design. [PMC free article: PMC3128563] [PubMed: 21551127]
  • Johanneson B, McDonnell SK, Karyadi DM, et al. Family-based association analysis of 42 hereditary prostate cancer families identifies the Apolipoprotein L3 region on chromosome 22q12 as a risk locus. Hum Mol Genet. 2010;19(19):3852–62. OVID-Medline. Exclude: Study Design. [PMC free article: PMC2935853] [PubMed: 20631155]
  • Johansson A, Marroni F, Hayward C, et al. Common variants in the JAZF1 gene associated with height identified by linkage and genome-wide association analysis. Hum Mol Genet. 2009;18(2):373–80. OVID-Embase. Exclude: Not about prostate cancer. [PMC free article: PMC2638782] [PubMed: 18952825]
  • Johansson M, McKay JD, Stattin P, et al. Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer. Int J Canc. 2007;120(3):539–42. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17096324]
  • Johansson M, McKay JD, Rinaldi S, et al. Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival. Prostate. 2009;69(12):1281–91. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 19455605]
  • Johansson M, McKay JD, Wiklund F, et al. Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk. Canc Epidemiol Biomarkers Prev. 2009;18(5):1644–50. OVID-Medline. Exclude: Test not commercially available. [PubMed: 19423539]
  • Johansson M, McKay JD, Wiklund F, et al. Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels. J Clin Endocrinol Metabol. 2007;92(12):4820–6. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17911177]
  • Johansson M, Van GB, Hultdin J, et al. The MTHFR 677C --> T polymorphism and risk of prostate cancer: Results from the CAPS study. Canc Causes Contr. 2007;18(10):1169–74. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17846906]
  • Jonsson BA, Adami HO, Hagglund M, et al. -160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. Int J Canc. 2004;109(3):348–52. OVID-Medline. Exclude: Test not commercially available. [PubMed: 14961571]
  • Joung JY, Lee YS, Park S, et al. Haplotype analysis of prostate stem cell antigen and association with prostate cancer risk. J Urol. 2011;185(6):2112–8. OVID-Embase. Exclude: Candidate gene study. [PubMed: 21497359]
  • Kader AK, Sun J, Isaacs SD, et al. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate. 2009;69(11):1195–205. OVID-Medline. Exclude: Doesn't include test panel. [PMC free article: PMC2852875] [PubMed: 19434657]
  • Kaklamani V, Baddi L, Rosman D, et al. No major association between TGFBR1*6A and prostate cancer. BMC Genet. 2004;5:28. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC521683] [PubMed: 15385056]
  • Kammerer S, Roth RB, Reneland R, et al. Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus. Canc Res. 2004;64(24):8906–10. OVID-Medline. Exclude: GWA study. [PubMed: 15604251]
  • Kang D, Lee KM, Park SK, et al. Lack of association of transforming growth factor-beta1 polymorphisms and haplotypes with prostate cancer risk in the prostate, lung, colorectal, and ovarian trial. Canc Epidemiol Biomarkers Prev. 2007;16(6):1303–5. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17548703]
  • Katafigiotis S, Papamichos SI, Katopodi R, et al. A case-control study on the rs3130932 single nucleotide polymorphism in the OCT4B translation initiation codon in association with cancer state. Eur J Canc Prev. 2011;20(3):248–51. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 21301344]
  • Kaur-Knudsen D, Nordestgaard BG, Bojesen SE. CYP2C9 genotype does not affect risk of tobacco-related cancer in the general population. Canc Epidemiol. 2010;34(2):178–83. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 20117066]
  • Kesarwani P, Mandhani A, Mittal RD. Polymorphisms in tumor necrosis factor-A gene and prostate cancer risk in North Indian cohort. J Urol. 2009;182(6):2938–43. OVID-Medline. Exclude: Test not commercially available. [PubMed: 19846139]
  • Kessler T, Wissenbach U, Grobholz R, et al. TRPV6 alleles do not influence prostate cancer progression. BMC Canc. 2009;9:380. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2774862] [PubMed: 19857260]
  • Kibel AS, Jin CH, Klim A, et al. Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. Prostate. 2008;68(11):1179–86. OVID-Medline. Exclude: Test not commercially available. [PubMed: 18459109]
  • Kibel AS, Suarez BK, Belani J, et al. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Canc Res. 2003;63(9):2033–6. OVID-Medline. Exclude: Test not commercially available. [PubMed: 12727815]
  • Kibel AS. Commentary on Cumulative association of five genetic variants with prostate cancer. Urol Oncol. 2009;27(4):462–3. OVID-Embase. Exclude: Not about prostate cancer.
  • Kibel AS. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Urol Oncol. 2007;25(5):447–8. OVID-Embase. Exclude: Not about prostate cancer.
  • Kidd LC, Paltoo DN, Wang S, et al. Sequence variation within the 5' regulatory regions of the vitamin D binding protein and receptor genes and prostate cancer risk. Prostate. 2005;64(3):272–82. OVID-Medline. Exclude: Test not commercially available. [PubMed: 15717311]
  • Kiessling AA. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Chemtracts. 2007;19(3):122–3. OVID-Embase. Exclude: SNP assessment in single gene.
  • Kim SR, Sai K, Tanaka-Kagawa T, et al. Haplotypes and a novel defective allele of CES2 found in a Japanese population. Drug Metabol Dispos. 2007;35(10):1865–72. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 17640957]
  • Kim SR, Saito Y, Maekawa K, et al. Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK) Drug Metabol Pharmacokinet. 2008;23(5):379–84. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 18974616]
  • Kim W, Yoo TK, Kim SJ, et al. Lack of association between Y-chromosomal haplogroups and prostate cancer in the Korean population. PLoS One. 2007;2(1):e172. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC1766463] [PubMed: 17245448]
  • Kirkland CT, Price DK, Figg WD. Genetic variant associated with aggressive not indolent prostate cancer. Canc Biol Ther. 2010;9(12):957–8. OVID-Medline. Exclude: Study Design. [PubMed: 20581469]
  • Klein RJ, Hallden C, Cronin AM, et al. Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: Kallikreins and prostate cancer. Canc Prev Res. 2010;3(5):611–9. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2865570] [PubMed: 20424135]
  • Knappskog S, Lonning PE. MDM2 promoter SNP285 and SNP309; Phylogeny and impact on cancer risk. Oncotarget. 2011;2(3):251–8. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC3260817] [PubMed: 21436469]
  • Kohli M, Rothberg PG, Feng C, et al. Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. Canc Biomarkers. 2010;7(2):101–8. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC3982319] [PubMed: 21178268]
  • Koike H, Suzuki K, Satoh T, et al. Cyclin D1 gene polymorphism and familial prostate cancer: The AA genotype of A870G polymorphism is associated with prostate cancer risk in men aged 70 years or older and metastatic stage. Anticancer Res. 2003;23(6D):4947–51. OVID-Medline. Exclude: Test not commercially available. [PubMed: 14981950]
  • Kote-Jarai Z, Jugurnauth S, Mulholland S, et al. A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer. Br J Canc. 2009;100(2):426–30. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2634720] [PubMed: 19127258]
  • Kote-Jarai Z, Amin Al OA, Leongamornlert D, et al. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet. 2011;129(6):687–94. OVID-Medline. Exclude: GWA study. [PMC free article: PMC3092928] [PubMed: 21465221]
  • Kote-Jarai Z, Easton DF, Stanford JL, et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL Consortium. Canc Epidemiol Biomarkers Prev. 2008;17(8):2052–61. OVID-Medline. Exclude: No test panel of human SNP. [PMC free article: PMC2776652] [PubMed: 18708398]
  • Kote-Jarai Z, Leongamornlert D, Tymrakiewicz M, et al. Mutation analysis of the MSMB gene in familial prostate cancer. Br J Canc. 2010;102(2):414–8. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2816656] [PubMed: 19997100]
  • Kote-Jarai Z, Olama AAA, Giles GG, et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet. 2011;43(8):785–91. OVID-Embase. Exclude: GWA study. [PMC free article: PMC3396006] [PubMed: 21743467]
  • Koutros S, Beane Freeman LE, Berndt SI, et al. Pesticide use modifies the association between genetic variants on chromosome 8q24 and prostate cancer. Canc Res. 2010;70(22):9224–33. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2982856] [PubMed: 20978189]
  • Koutros S, Schumacher FR, Hayes RB, et al. Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. Canc Res. 2010;70(6):2389–96. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2840184] [PubMed: 20197460]
  • Koutros S, Andreotti G, Berndt SI, et al. Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer. Pharmacogenetics Genom. 2011;21(10):615–23. OVID-Embase. Exclude: Candidate gene study. [PMC free article: PMC3172373] [PubMed: 21716162]
  • Koutros S, Berndt SI, Sinha R, et al. Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer. Canc Res. 2009;69(5):1877–84. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2662592] [PubMed: 19223546]
  • Kraft P, Pharoah P, Chanock SJ, et al. Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet. 2005;1(5):e68. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC1287955] [PubMed: 16311626]
  • Ku CS, Teo SM, Naidoo N, et al. Copy number polymorphisms in new HapMap III and Singapore populations. J Hum Genet. 2011;56(8):552–60. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 21677662]
  • Kuasne H, Rodrigues IS, Fuganti PE, et al. Polymorphisms in the AR and PSA genes as markers of susceptibility and aggressiveness in prostate cancer. Canc Invest. 2010;28(9):917–24. OVID-Embase. Exclude: Candidate gene study. [PubMed: 20632874]
  • Kumar V, Yadav CS, Singh S, et al. CYP 1A1 polymorphism and organochlorine pesticides levels in the etiology of prostate cancer. Chemosphere. 2010;81(4):464–8. OVID-Medline. Exclude: Test not commercially available. [PubMed: 20817259]
  • Kumpf O, Hamann L, Schlag PM, et al. Pre- and postoperative cytokine release after in vitro whole blood lipopolysaccharide stimulation and frequent toll-like receptor 4 polymorphisms. Shock. 2006;25(2):123–8. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 16525349]
  • Kurosaki T, Suzuki M, Enomoto Y, et al. Polymorphism of cytochrome P450 2B6 and prostate cancer risk: A significant association in a Japanese population. Int J Urol. 2009;16(4):364–8. OVID-Medline. Exclude: Test not commercially available. [PubMed: 19425200]
  • Kwon DD, Lee JW, Han DY, et al. Relationship between the glutathione-S-transferase P1, M1, and T1 genotypes and prostate cancer risk in Korean subjects. K J Urol. 2011;52(4):247–52. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC3085616] [PubMed: 21556210]
  • Kwon EM, Salinas CA, Kolb S, et al. Genetic polymorphisms in inflammation pathway genes and prostate cancer risk. Canc Epidemiol Biomarkers Prev. 2011;20(5):923–33. OVID-Embase. Exclude: Candidate gene study. [PMC free article: PMC3140053] [PubMed: 21430300]
  • Lai J, Kedda MA, Hinze K, et al. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis. 2007;28(5):1032–9. OVID-Embase. Exclude: Test not commercially available. [PubMed: 17151093]
  • Lamb DJ, Tannour-Louet M. In vivo exploration of the functional activity of the non-coding 8q24 prostate cancer risk locus. Asian J Androl. 2010;12(6):787–9. OVID-Embase. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3739063] [PubMed: 20818410]
  • Lange EM, Beebe-Dimmer JL, Ray AM, et al. Genome-wide linkage scan for prostate cancer susceptibility from the University of Michigan Prostate Cancer Genetics Project: Suggestive evidence for linkage at 16q23. Prostate. 2009;69(4):385–91. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2712837] [PubMed: 19035517]
  • Langeberg WJ, Tahir SA, Feng Z, et al. Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate. 2010;70(9):1020–35. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2875326] [PubMed: 20209490]
  • Langeberg WJ, Kwon EM, Koopmeiners JS, et al. Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes. Canc Epidemiol Biomarkers Prev. 2010;19(1):258–64. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2825566] [PubMed: 20056646]
  • Langsenlehner T, Thurner EM, Renner W, et al. Association between single nucleotiDe polymorphisms and haplotypes in the vegf gene and late toxicity in prostate cancer patients. Radiother Oncol; Conference: ESTRO Anniversary - GEC-ESTRO - EIOF - 11th Biennial; London United Kingdom. 2011. pp. S349–S350. OVID-Embase. Exclude: Study Design.
  • Langsenlehner T, Renner W, Gerger A, et al. Association between single nucleotide polymorphisms in the gene for XRCC1 and radiation-induced late toxicity in prostate cancer patients. Radiother Oncol. 2011;98(3):387–93. OVID-Embase. Exclude: SNP assessment in single gene. [PubMed: 21345510]
  • Langsenlehner T, Langsenlehner U, Renner W, et al. Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer. Eur J Canc. 2008;44(11):1572–6. OVID-Medline. Exclude: Test not commercially available. [PubMed: 18514506]
  • Langsenlehner T, Kapp KS, Langsenlehner U. TGFB1 single-nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. In regard to Peters et al. Int J Radiat Oncol Biol Phys. 2008;71(3):960. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 18514790]
  • Langsenlehner T, Langsenlehner U, Renner W, et al. The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases. Prostate. 2008;68(3):264–8. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 18163425]
  • Larson GP, Ding Y, Cheng LS, et al. Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT. Canc Res. 2005;65(3):805–14. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 15705877]
  • Lavender NA, Benford ML, VanCleave TT, et al. Examination of polymorphic glutathione S-transferase (GST) genes, tobacco smoking and prostate cancer risk among men of African descent: A case-control study. BMC Canc. 2009;9:397. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2783040] [PubMed: 19917083]
  • Lavender NA, Komolafe OO, Benford M, et al. No association between variant DNA repair genes and prostate cancer risk among men of African descent. Prostate. 2010;70(2):113–9. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2798907] [PubMed: 19760636]
  • Le Cao KA, Boitard S, Besse P. Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems. BMC Bioinformatics. 2011;12:253. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC3133555] [PubMed: 21693065]
  • Lee KM, Kang D, Park SK, et al. Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis. 2009;30(4):621–5. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2664454] [PubMed: 19168583]
  • Leskela S, Jara C, Leandro-Garcia LJ, et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J. 2011;11(2):121–9. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 20212519]
  • Levin AM, Ray AM, Zuhlke KA, et al. Association between germline variation in the FHIT gene and prostate cancer in Caucasians and African Americans. Canc Epidemiol Biomarkers Prev. 2007;16(6):1294–7. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17548701]
  • Levin AM, Machiela MJ, Zuhlke KA, et al. Chromosome 17q12 variants contribute to risk of early-onset prostate cancer. Canc Res. 2008;68(16):6492–5. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2562290] [PubMed: 18701471]
  • Levin AM, Zuhlke KA, Ray AM, et al. Sequence variation in alpha-methylacyl-CoA racemase and risk of early-onset and familial prostate cancer. Prostate. 2007;67(14):1507–13. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17683075]
  • Lewis SJ, Murad A, Chen L, et al. Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. PLoS One. 2010;5(10):e13485. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC2957440] [PubMed: 20976066]
  • Li H, Bubley GJ, Balk SP, et al. Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. Prostate. 2007;67(12):1354–61. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17624927]
  • Li H, Shinohara ET, Cai Q, et al. Plasminogen activator inhibitor-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer. Clin Oncol. 2006;18(4):333–7. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16703752]
  • Li HC, Albert JM, Shinohara ET, et al. E-cadherin promoter polymorphisms are not associated with the aggressiveness of prostate cancer in Caucasian patients. Urol Oncol-Semin O I. 2006;24(6):496–502. OVID-Embase. Exclude: Test not commercially available. [PubMed: 17138130]
  • Li L, Cicek MS, Casey G, et al. No association between genetic polymorphisms in insulin and insulin receptor substrate-1 and prostate cancer. Canc Epidemiol Biomarkers Prev. 2005;14(10):2462–3. OVID-Medline. Exclude: Study Design. [PubMed: 16214935]
  • Li M, Guan TY, Li Y, et al. Polymorphisms of GSTM1 and CYP1A1 genes and their genetic susceptibility to prostate cancer in Chinese men. Chin Med J. 2008;121(4):305–8. OVID-Embase. Exclude: Did not use SNP assembled panel. [PubMed: 18304461]
  • Licastro F, Bertaccini A, Porcellini E, et al. Alpha 1 antichymotrypsin genotype is associated with increased risk of prostate carcinoma and PSA levels. Anticancer Res. 2008;28(1B):395–9. OVID-Medline. Exclude: SNP assessment in single gene. [PubMed: 18383875]
  • Lieberfarb ME, Lin M, Lechpammer M, et al. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Canc Res. 2003;63(16):4781–5. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 12941794]
  • Lilja H. Holistic view on the prostate-specific antigen (PSA) and kallikrein-related peptidase 2 (HK2), and their association with the risk or outcome of prostate cancer. Tumor Biol; Conference: 38th Meeting of the International Society of Oncology and BioMarkers, ISOBM; Munchen Germany. 2010. p. S29. OVID-Embase. Exclude: Study Design.
  • Lin CC, Wu HC, Chen WC, et al. CYP17 gene promoter allelic variant is not associated with prostate cancer. Urol Oncol. 2003;21(4):262–5. OVID-Medline. Exclude: No test panel of human SNP. [PubMed: 12954495]
  • Lin CC, Wu HC, Tsai FJ, et al. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. Urol. 2003;62(2):374–7. OVID-Medline. Exclude: No test panel of human SNP. [PubMed: 12893367]
  • Lin DW, Fitzgerald LM, Fu R, et al. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Canc Epidemiol Biomarkers Prev. 2011;20(9):1928–36. OVID-Embase. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3169727] [PubMed: 21846818]
  • Lin HY, Wang W, Liu YH, et al. Comparison of multivariate adaptive regression splines and logistic regression in detecting SNP-SNP interactions and their application in prostate cancer. J Hum Genet. 2008;53(9):802–11. OVID-Medline. Exclude: Study Design. [PubMed: 18607530]
  • Lindmark F, Zheng SL, Wiklund F, et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Canc Inst. 2004;96(16):1248–54. OVID-Medline. Exclude: Test not commercially available. [PubMed: 15316060]
  • Lindmark F, Zheng SL, Wiklund F, et al. Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk. Br J Canc. 2005;93(4):493–7. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC2361575] [PubMed: 16106254]
  • Lindstrom S, Ma J, Altshuler D, et al. A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. J Clin Endocrinol Metabol. 2010;95(9):E121–7. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC2936075] [PubMed: 20534771]
  • Lindstrom S, Schumacher F, Siddiq A, et al. Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers-results from BPC3. PLoS One. 2011;6(2):e17142. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC3044744] [PubMed: 21390317]
  • Lindstrom S, Wiklund F, Jonsson BA, et al. Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: Strong confirmation of functional promoter SNP. Hum Genet. 2005;118(3-4):339–47. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16189707]
  • Lindstrom S, Adami HO, Balter K, et al. Genetic variation in the upstream region of ERG and prostate cancer. Canc Causes Contr. 2009;20(7):1173–80. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC3755494] [PubMed: 19205910]
  • Lindstrom S, Wiklund F, Adami HO, et al. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development. Canc Res. 2006;66(22):11077–83. OVID-Medline. Exclude: Candidate gene study. [PubMed: 17108148]
  • Lindstrom S, Adami HO, Balter KA, et al. Inherited variation in hormone-regulating genes and prostate cancer survival. Clin Canc Res. 2007;13(17):5156–61. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 17785571]
  • Lindstrom S, Hunter DJ, Gronberg H, et al. Sequence variants in the TLR4 and TLR6-1-10 genes and prostate cancer risk. Results based on pooled analysis from three independent studies. Canc Epidemiol Biomarkers Prev. 2010;19(3):873–6. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2837532] [PubMed: 20200442]
  • Lindstrom S, Zheng SL, Wiklund F, et al. Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway. Prostate. 2006;66(16):1729–43. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 16998812]
  • Lindstrom S, Adami HO, Adolfsson J, et al. Y chromosome haplotypes and prostate cancer in Sweden. Clin Canc Res. 2008;14(20):6712–6. OVID-Medline. Exclude: Candidate gene study. [PubMed: 18927315]
  • Lisitskaya KV, Krakhmaleva IN, Shishkin SS. Study of single-nucleotide polymorphism in seven genes (GHR, IGFBP3, IGFR1, IRS1, FMN1, ANXA2, TAGLN) in ethnic Russians and patients with prostate cancer. Mol Genet Microbiol Virol. 2010;25(2):84–8. OVID-Embase. Exclude: Test not commercially available. [PubMed: 20540360]
  • Liu J, Song B, Bai X, et al. Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC Canc. 2010;10:456. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2936329] [PubMed: 20735825]
  • Liu J, Zhang JS, Young CYF, et al. Polymorphisms of prostate-specific antigen gene promoter: Determination from cord blood collected on filter paper. Ann Clin Lab Sci. 2003;33(4):429–34. OVID-Embase. Exclude: Doesn't include test panel. [PubMed: 14584757]
  • Liu JH, Li HW, Gu L, et al. Single nucleotide polymorphisms in the 3' region of vitamin D receptor gene and the genetic risk of prostate cancer in Chinese population. Chin J Clin Rehabil. 2004;8(17):3429–32. OVID-Embase. Exclude: Test not commercially available.
  • Liu L, Liu L, Zeng F, et al. Meta-analysis of the association between VEGF-634 G>C and risk of malignancy based on 23 case-control studies. J Canc Res Clin Oncol. 2011;137(6):1027–36. OVID-Medline. Exclude: Study Design. [PubMed: 21174216]
  • Liu M, Suzuki M, Arai T, et al. A replication study examining three common single-nucleotide polymorphisms and the risk of prostate cancer in a Japanese population. Prostate. 2011;71(10):1023–32. OVID-Embase. Exclude: Test not commercially available. [PubMed: 21557267]
  • Liu M, Kurosaki T, Suzuki M, et al. Significance of common variants on human chromosome 8q24 in relation to the risk of prostate cancer in native Japanese men. BMC Genet. 2009;10:37. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2719668] [PubMed: 19602258]
  • Liu W, Sun J, Li G, et al. Association of a germ-line copy number variation at 2p24.3 and risk for aggressive prostate cancer. Canc Res. 2009;69(6):2176–9. OVID-Medline. Exclude: GWA study. [PMC free article: PMC2743179] [PubMed: 19258504]
  • Liu W, Chang B, Sauvageot J, et al. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Gene Chromosome Canc. 2006;45(11):1018–32. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 16897747]
  • Liu W, Laitinen S, Khan S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009;15(5):559–65. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2839160] [PubMed: 19363497]
  • Liu W, Chang BL, Cramer S, et al. Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. Clin Canc Res. 2007;13(17):5028–33. OVID-Medline. Exclude: Candidate gene study. [PubMed: 17785553]
  • Liu W, Xie CC, Zhu Y, et al. Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia. 2008;10(8):897–907. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2481576] [PubMed: 18670647]
  • Liu W, Ewing CM, Chang BL, et al. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. Gene Chromosome Canc. 2007;46(11):972–80. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 17654723]
  • Liu X, Cicek MS, Plummer SJ, et al. Association of testis derived transcript gene variants and prostate cancer risk. J Urol. 2007;177(3):894–8. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17296370]
  • Liu X, Cheng I, Plummer SJ, et al. Fine-mapping of prostate cancer aggressiveness loci on chromosome 7q22-35. Prostate. 2011;71(7):682–9. OVID-Embase. Exclude: Study Design. [PMC free article: PMC3027848] [PubMed: 20945404]
  • Liu X, Plummer SJ, Nock NL, et al. Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: Modification by lymphotoxin alpha. Am J Epidemiol. 2006;164(10):984–9. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16931544]
  • Liu Y, Lin N, Huang L, et al. Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol. 2007;26(8):613–8. OVID-Embase. Exclude: Test not commercially available. [PubMed: 17688413]
  • Loeb S, Helfand BT, Kan D, et al. Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness? BJU Int. 2009;104(9):1200–3. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC3168555] [PubMed: 19627283]
  • Loeb S, Carter HB, Walsh PC, et al. Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. J Urol. 182(1):101–4. 105. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 19450841]
  • Loh YH, Mitrou PN, Bowman R, et al. MGMT Ile143Val polymorphism, dietary factors and the risk of breast, colorectal and prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk study. DNA Repair. 2010;9(4):421–8. OVID-Medline. Exclude: SNP assessment in single gene. [PubMed: 20096652]
  • Loh YH, Mitrou PN, Wood A, et al. SMAD7 and MGMT genotype variants and cancer incidence in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk Study. Canc Epidemiol. 2011;35(4):369–74. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 21075068]
  • Lou H, Yeager M, Li H, et al. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci USA. 2009;106(19):7933–8. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2671324] [PubMed: 19383797]
  • Loukola A, Chadha M, Penn SG, et al. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2. Eur J Hum Genet. 2004;12(4):321–32. OVID-Medline. Exclude: Study Design. [PubMed: 14560315]
  • Low YL, Taylor JI, Grace PB, et al. Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk. Nutr Canc. 2006;56(1):31–9. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17176215]
  • Lu L, Sun J, Isaacs SD, et al. Fine-mapping and family-based association analyses of prostate cancer risk variants at Xp11. Canc Epidemiol Biomarkers Prev. 2009;18(7):2132–6. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2795389] [PubMed: 19549809]
  • Lu Y, Zhang Z, Yu H, et al. Functional annotation of risk loci identified through genome-wide association studies for prostate cancer. Prostate. 2011;71(9):955–63. OVID-Embase. Exclude: Study Design. [PMC free article: PMC3070182] [PubMed: 21541972]
  • Lubahn J, Berndt SI, Jin CH, et al. Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. Prostate. 2010;70(6):646–53. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC3072829] [PubMed: 20033885]
  • Lundin KB, Nordenskjold A, Giwercman A, et al. Frequent finding of the androgen receptor A645D variant in normal population. J Clin Endocrinol Metabol. 2006;91(8):3228–31. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16705072]
  • Machiela MJ, Chen CY, Chen C, et al. Evaluation of polygenic risk scores for predicting breast and prostate cancer risk. Genet Epidemiol. 2011;35(6):506–14. OVID-Embase. Exclude: Did not use SNP assembled panel. [PMC free article: PMC4089860] [PubMed: 21618606]
  • MacInnis RJ, Antoniou AC, Eeles RA, et al. A risk prediction algorithm based on family history and common genetic variants: Application to prostate cancer with potential clinical impact. Genet Epidemiol. 2011;35(6):549–56. OVID-Embase. Exclude: Study Design. [PMC free article: PMC3950816] [PubMed: 21769933]
  • Maier C, Rosch K, Herkommer K, et al. A candidate gene approach within the susceptibility region PCaP on 1q42.2-43 excludes deleterious mutations of the PCTA-1 gene to be responsible for hereditary prostate cancer. Eur Urol. 2002;42(3):301–7. OVID-Medline. Exclude: Test not commercially available. [PubMed: 12234517]
  • Maistro S, Snitcovsky I, Sarkis AS, et al. Vitamin D receptor polymorphisms and prostate cancer risk in Brazilian men. Int J Biol Markers. 2004;19(3):245–9. OVID-Medline. Exclude: Test not commercially available. [PubMed: 15503828]
  • Mandal RK, Gangwar R, Mandhani A, et al. DNA repair gene X-ray repair cross-complementing group 1 and xeroderma pigmentosum group D polymorphisms and risk of prostate cancer: A study from. North India DNA Cell Biol. 2010;29(4):183–90. OVID-Medline. Exclude: Test not commercially available. [PubMed: 20070155]
  • Mandal RK, Singh V, Kapoor R, et al. Do polymorphisms in XRCC4 influence prostate cancer susceptibility in North Indian population? Biomarkers. 2011;16(3):236–42. OVID-Medline. Exclude: Test not commercially available. [PubMed: 21506695]
  • Mandal RK, Kapoor R, Mittal RD. Polymorphic variants of DNA repair gene XRCC3 and XRCC7 and risk of prostate cancer: A study from North Indian population. DNA Cell Biol. 2010;29(11):669–74. OVID-Medline. Exclude: Test not commercially available. [PubMed: 20590474]
  • Marangoni K, Araujo TG, Neves AF, et al. The -786T>C promoter polymorphism of the NOS3 gene is associated with prostate cancer progression. BMC Canc. 2008;8:273. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2571109] [PubMed: 18823560]
  • Marchesani M, Hakkarainen A, Tuomainen TP, et al. New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men. J Natl Canc Inst. 2003;95(11):812–8. OVID-Embase. Exclude: Test not commercially available. [PubMed: 12783936]
  • Margiotti K, Kim E, Pearce CL, et al. Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men. Prostate. 2002;53(1):65–8. OVID-Medline. Exclude: Test not commercially available. [PubMed: 12210481]
  • Marini F, Tonelli P, Cavalli L, et al. Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Front Biosci. 2011;3:364–70. OVID-Medline. Exclude: Test not commercially available. [PubMed: 21196316]
  • Mason TE, Ricks-Santi L, Chen W, et al. Association of CD14 variant with prostate cancer in African American men. Prostate. 2010;70(3):262–9. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC3046920] [PubMed: 19830784]
  • McCarron SL, Edwards S, Evans PR, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Canc Res. 2002;62(12):3369–72. OVID-Medline. Exclude: Test not commercially available. [PubMed: 12067976]
  • McKay JD, Kaaks R, Johansson M, et al. Haplotype-based analysis of common variation in the growth hormone receptor gene and prostate cancer risk. Canc Epidemiol Biomarkers Prev. 2007;16(1):169–73. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17220348]
  • Medeiros R, Morais A, Vasconcelos A, et al. Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Canc Prev. 2002;11(4):343–50. OVID-Embase. Exclude: Test not commercially available. [PubMed: 12195160]
  • Medeiros R, Vasconcelos A, Costa S, et al. Metabolic susceptibility genes and prostate cancer risk in a southern European population: The role of glutathione S-transferases GSTM1, GSTM3, and GSTT1 genetic polymorphisms. Prostate. 2004;58(4):414–20. OVID-Medline. Exclude: Test not commercially available. [PubMed: 14968442]
  • Meenakshisundaram R, Piumelli N, Pierpaoli L, et al. CHOP 5'UTR-c.279T>C and +nt30C>T variants are not associated with overweight condition or with tumors/cancer in Italians - a case-control study. JECCR. 2009;28:90. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC2711059] [PubMed: 19558691]
  • Meiri E, Levy A, Benjamin H, et al. Discovery of microRNAs and other small RNAs in solid tumors. Nucleic Acids Res. 2010;38(18):6234–46. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC2952848] [PubMed: 20483914]
  • Meitz JC, Edwards SM, Easton DF, et al. HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease. Br J Canc. 2002;87(8):905–8. OVID-Medline. Exclude: Study design. [PMC free article: PMC2376179] [PubMed: 12373607]
  • Metharom E, Galettis P, Manners S, et al. The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C. Asia-Pacific Journal of Clinical Oncology. 2011;7(1):65–74. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 21332653]
  • Meyer A, Schurmann P, Ghahremani M, et al. Association of chromosomal locus 8q24 and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy. Urol Oncol. 2009;27(4):373–6. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 18625567]
  • Meyer KB, Maia AT, O'Reilly M, et al. A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression. PLoS Genet. 2011;7(7):e1002165. OVID-Embase. Exclude: No test panel of human SNP. [PMC free article: PMC3140991] [PubMed: 21814516]
  • Meyer MS, Penney KL, Stark JR, et al. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010;31(9):1597–603. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2930803] [PubMed: 20576793]
  • Meyer TE, Boerwinkle E, Morrison AC, et al. Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study. Canc Epidemiol Biomarkers Prev. 2010;19(2):558–65. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2820124] [PubMed: 20142250]
  • Miaskowski C, Dodd M, Lee K, et al. Preliminary evidence of an association between a functional interleukin-6 polymorphism and fatigue and sleep disturbance in oncology patients and their family caregivers. J Pain Symptom Manag. 2010;40(4):531–44. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC2952712] [PubMed: 20570482]
  • Michaud DS, Daugherty SE, Berndt SI, et al. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Canc Res. 2006;66(8):4525–30. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16618781]
  • Mikhak B, Hunter DJ, Spiegelman D, et al. Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. Carcinogenesis. 2008;29(12):2335–40. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2722865] [PubMed: 18784358]
  • Mikhak B, Hunter DJ, Spiegelman D, et al. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate. 2007;67(9):911–23. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17440943]
  • Mimori K, Kida H, Tanaka J, et al. Single nucleotide polymorphism of fibronectin-1, determining tumor shape and malignant behavior in colorectal cancer cases. Ann Surg Oncol; Conference: 64th Annual Cancer Symposium of the Society of Surgical Oncology; San Antonio, TX United States. 2011. p. S131. OVID-Embase. Exclude: Not about prostate cancer.
  • Minarik M, Benesova L, Fantova L, et al. Parallel optimization and genotyping of multiple single-nucleotide polymorphism markers by sample pooling approach using cycling-gradient CE with multiple injections. Electrophoresis. 2006;27(19):3856–63. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 16972303]
  • Mino C, Witte T, Robles P, et al. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population. Canc Genet Cytogenet. 2009;189(2):71–6. OVID-Medline. Exclude: Test not commercially available. [PubMed: 19215786]
  • Mirabello L, Yu K, Kraft P, et al. The association of telomere length and genetic variation in telomere biology genes. Hum Mutat. 2010;31(9):1050–8. OVID-Embase. Exclude: Not about prostate cancer. [PMC free article: PMC2932868] [PubMed: 20597107]
  • Mittal RD, George GP, Mishra J, et al. Role of functional polymorphisms of P53 and P73 genes with the risk of prostate cancer in a case-control study from Northern India. Arch Med Res. 2011;42(2):122–7. OVID-Embase. Exclude: Test not commercially available. [PubMed: 21565625]
  • Mononen N, Seppala EH, Duggal P, et al. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Canc Res. 2006;66(2):743–7. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 16424004]
  • Moon S, Holley S, Bodiwala D, et al. Associations between G/A1229, A/G3944, T/C30875, C/T48200 and C/T65013 genotypes and haplotypes in the vitamin D receptor gene, ultraviolet radiation and susceptibility to prostate cancer. Ann Hum Genet. 2006;70(Pt:2):2–36. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16626332]
  • Moore SC, Leitzmann MF, Albanes D, et al. Adipokine genes and prostate cancer risk. Int J Canc. 2009;124(4):869–76. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC2879625] [PubMed: 19035456]
  • Moore SC, Leitzmann MF, Weinstein SJ, et al. Insulin resistance-related gene polymorphisms and risk of prostate cancer. Canc Epidemiol Biomarkers Prev. 2007;16(6):1315–7. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17548707]
  • Mori M, Masumori N, Fukuta F, et al. Weight gain and family history of prostate or breast cancers as risk factors for prostate cancer: Results of a case-control study in Japan. Asian Pac J Canc Prev. 2011;12(3):743–7. OVID-Embase. Exclude: No test panel of human SNP. [PubMed: 21627376]
  • Morote J, Del AJ, Borque A, et al. Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms. J Urol. 2010;184(2):506–11. OVID-Medline. Exclude: Doesn't include test panel. [PubMed: 20620409]
  • Morton LM, Wang SS, Bergen AW, et al. DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Pharmacogenetics Genom. 2006;16(12):901–10. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 17108814]
  • Murabito JM, Rosenberg CL, Finger D, et al. A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study. BMC Med Genet. 2007;8(Suppl 1):S6. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC1995609] [PubMed: 17903305]
  • Murad A, Lewis SJ, Smith GD, et al. PTGS2-899G>C and prostate cancer risk: A population-based nested case-control study (ProtecT) and a systematic review with meta-analysis. Prostate Canc P Dis. 2009;12(3):296–300. OVID-Medline. Exclude: Test not commercially available. [PubMed: 19488068]
  • Murad AS, Smith GD, Lewis SJ, et al. A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: Findings from a population-based, case-control study (the ProtecT study) Int J Mol Epidemiol Genet. 2010;1(3):175–83. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC3076770] [PubMed: 21537389]
  • Murant SJ, Rolley N, Phillips SM, et al. Allelic imbalance within the E-cadherin gene is an infrequent event in prostate carcinogenesis. Gene Chromosome Canc. 2000;27(1):104–9. OVID-Medline. Exclude: Study design. [PubMed: 10564592]
  • Nam RK, Zhang WW, Loblaw DA, et al. A genome-wide association screen identifies regions on chromosomes 1q25 and 7p21 as risk loci for sporadic prostate cancer. Prostate Canc P Dis. 2008;11(3):241–6. OVID-Medline. Exclude: Study Design. [PubMed: 17876339]
  • Nam RK, Zhang WW, Trachtenberg J, et al. Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection. J Clin Oncol. 2003;21(12):2312–9. OVID-Medline. Exclude: No test panel of human SNP. [PubMed: 12805332]
  • Nam RK, Zhang WW, Jewett MA, et al. The use of genetic markers to determine risk for prostate cancer at prostate biopsy. Clin Canc Res. 2005;11(23):8391–7. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16322300]
  • Nam RK, Zhang WW, Klotz LH, et al. Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy. Clin Canc Res. 2006;12(21):6452–8. OVID-Medline. Exclude: SNP assessment in single gene. [PubMed: 17085659]
  • Nangia-Makker P, Wang Y, Raz T, et al. Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Canc. 2010;127(11):2530–41. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC3334857] [PubMed: 20162566]
  • Narita S, Tsuchiya N, Wang L, et al. Association of lipoprotein lipase gene polymorphism with risk of prostate cancer in a Japanese population. Int J Canc. 2004;112(5):872–6. OVID-Medline. Exclude: Test not commercially available. [PubMed: 15386377]
  • Narla G, Difeo A, Reeves HL, et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Canc Res. 2005;65(4):1213–22. OVID-Medline. Exclude: Test not commercially available. [PubMed: 15735005]
  • Narla G, Difeo A, Yao S, et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Canc Res. 2005;65(13):5761–8. OVID-Embase. Exclude: Did not use SNP assembled panel. [PubMed: 15994951]
  • Navratil V, Penel S, Delmotte S, et al. DigiPINS: A database for vertebrate exonic single nucleotide polymorphisms and its application to cancer association studies. Biochimie. 2008;90(4):563–9. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 17988782]
  • Nguyen PL, Ma J, Chavarro JE, et al. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010;28(25):3958–64. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2940394] [PubMed: 20679621]
  • Ning B, Wang C, Morel F, et al. Human glutathione S-transferase A2 polymorphisms: Variant expression, distribution in prostate cancer cases/controls and a novel form. Pharmacogenet. 2004;14(1):35–44. OVID-Embase. Exclude: Test not commercially available. [PubMed: 15128049]
  • Nock NL, Tang D, Rundle A, et al. Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race. Canc Epidemiol Biomarkers Prev. 2007;16(6):1236–45. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2151314] [PubMed: 17548691]
  • Noonan-Wheeler FC, Wu W, Roehl KA, et al. Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Prostate. 2006;66(1):49–56. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16114055]
  • Nurminen R, Wahlfors T, Tammela TLJ, et al. Identification of an aggressive prostate cancer predisposing variant at 11q13. Int J Canc. 2011;129(3):599–606. OVID-Embase. Exclude: Test not commercially available. [PubMed: 21064104]
  • Oakley-Girvan I, Feldman D, Eccleshall TR, et al. Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Canc Epidemiol Biomarkers Prev. 2004;13(8):1325–30. OVID-Embase. Exclude: Test not commercially available. [PubMed: 15298953]
  • Oh SS, Chang SC, Cai L, et al. Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers. Int J Canc. 2010;127(9):2169–82. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC2932751] [PubMed: 20112337]
  • Okobia MN, Zmuda JM, Ferrell RE, et al. Chromosome 8q24 variants are associated with prostate cancer risk in a high risk population of African ancestry. Prostate. 2011;71(10):1054–63. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC4422491] [PubMed: 21557270]
  • Okugi H, Nakazato H, Matsui H, et al. Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population. Canc Detect Prev. 2006;30(3):262–8. OVID-Embase. Exclude: Test not commercially available. [PubMed: 16859836]
  • Omrani MD, Taghipour-Bazargani S, Salari-Lak S, et al. Association of codon 10 polymorphism of the transforming growth factor beta 1 gene with prostate cancer and hyperplasia in an Iranian population. Urol Int. 2009;83(3):329–32. OVID-Embase. Exclude: Test not commercially available. [PubMed: 19829035]
  • Omrani MD, Bazargani S, Bageri M. Interlukin-10, interferon- and tumor necrosis factor-alpha genes variation in prostate cancer and benign prostatic hyperplasia. Curr Urol. 2008;2(4):175–80. OVID-Embase. Exclude: Test not commercially available.
  • Onen IH, Ekmekci A, Eroglu M, et al. Association of genetic polymorphisms in vitamin D receptor gene and susceptibility to sporadic prostate cancer. Exp Biol Med. 2008;233(12):1608–14. OVID-Medline. Exclude: Test not commercially available. [PubMed: 18849534]
  • Onen IH, Ekmekci A, Eroglu M, et al. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population. DNA Cell Biol. 2007;26(2):100–7. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17328668]
  • Onsory K, Sobti RC, Al-Badran AI, et al. Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population. Mol Cell Biochem. 2008;314(1-2):25–35. OVID-Medline. Exclude: Test not commercially available. [PubMed: 18483761]
  • Orr-Urtreger A, Bar-Shira A, Matzkin H, et al. The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 alpha is associated with increased risk for prostate cancer. Prostate. 2007;67(1):8–13. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16998808]
  • Osborne NJ, Gurrin LC, Allen KJ, et al. HFE c282y homozygotes are at increased risk of breast and colorectal cancer. Hepatol. 2010;51(4):1311–8. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC3815603] [PubMed: 20099304]
  • Ou J, Li K, Ren H, et al. Association and haplotype analysis of prostate stem cell antigen with gastric cancer in Tibetans. DNA Cell Biol. 2010;29(6):319–23. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 20230293]
  • Pal P, Xi H, Guha S, et al. Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry. Prostate. 2009;69(14):1548–56. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC3562713] [PubMed: 19562729]
  • Pal P, Xi H, Sun G, et al. Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin. Hum Genet. 2007;122(3-4):251–9. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 17593395]
  • Pal P, Xi H, Kaushal R, et al. Variants in the HEPSIN gene are associated with prostate cancer in men of European origin. Hum Genet. 2006;120(2):187–92. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16783571]
  • Paltoo D, Woodson K, Taylor P, et al. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene and risk of prostate cancer among men in a large cancer prevention study. Canc Lett. 2003;191(1):67–74. OVID-Medline. Exclude: SNP assessment in single gene. [PubMed: 12609711]
  • Panguluri RC, Long LO, Chen W, et al. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis. 2004;25(6):961–6. OVID-Medline. Exclude: Test not commercially available. [PubMed: 14754878]
  • Papanikolopoulou A, Landt O, Reczko M, et al. Association study of the single nucleotide polymorphism (SNP), rs6983267, at region 3 of chromosome 8q24, with prostate cancer in the Greek population. Rev Clin Pharmacol Pharmacokinet. 2010;24(2):187–9. OVID-Embase. Exclude: Test not commercially available.
  • Parikh H, Deng Z, Yeager M, et al. A comprehensive resequence analysis of the KLK15-KLK3-KLK2 locus on chromosome 19q13.33. Hum Genet. 2010;127(1):91–9. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2793378] [PubMed: 19823874]
  • Parikh H, Wang Z, Pettigrew KA, et al. Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels. Hum Genet. 2011;129(6):675–85. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC3092924] [PubMed: 21318478]
  • Parisi F, Ariyan S, Narayan D, et al. Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies. BMC Genomics. 2011;12:230. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC3114747] [PubMed: 21569352]
  • Park K, Kim JH, Jeon HG, et al. Influence of IGFBP3 gene polymorphisms on IGFBP3 serum levels and the risk of prostate cancer in low-risk Korean men. Urol. 2010;75(6):1516–7. OVID-Medline. Exclude: Test not commercially available. [PubMed: 20350746]
  • Pastina I, Giovannetti E, Chioni A, et al. Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. BMC Canc. 2010;10 Article Number: 511: OVID-Embase. Exclude: Not about prostate cancer. [PMC free article: PMC2955042] [PubMed: 20875115]
  • Patel AV, Cheng I, Canzian F, et al. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3) PLoS One. 2008;3(7):e2578. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC2440354] [PubMed: 18596909]
  • Penney KL, Schumacher FR, Li H, et al. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Canc Prev Res. 2010;3(5):604–10. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC2865569] [PubMed: 20424130]
  • Penney KL, Schumacher FR, Kraft P, et al. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis. 2011;32(6):853–9. OVID-Embase. Exclude: Candidate gene study. [PMC free article: PMC3106437] [PubMed: 21421545]
  • Perez CA, Chen H, Shyr Y, et al. The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer. J Urol. 2010;183(5):2062–9. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC4165525] [PubMed: 20303520]
  • Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Canc Res. 2006;66(17):8337–41. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 16951139]
  • Pierce BL, Biggs ML, DeCambre M, et al. C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Canc Causes Contr. 2009;20(7):1193–203. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2846958] [PubMed: 19267250]
  • Pierce BL, Ahsan H. Genetic susceptibility to type 2 diabetes is associated with reduced prostate cancer risk. Hum Hered. 2010;69(3):193–201. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2866577] [PubMed: 20203524]
  • Pomerantz MM, Werner L, Xie W, et al. Association of prostate cancer risk loci with disease aggressiveness and prostate cancer-specific mortality. Canc Prev Res. 2011;4(5):719–28. OVID-Embase. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3811002] [PubMed: 21367958]
  • Pomerantz MM, Beckwith CA, Regan MM, et al. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Canc Res. 2009;69(13):5568–74. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2884104] [PubMed: 19549893]
  • Pookot D, Li LC, Tabatabai ZL, et al. The E-cadherin -160 C/A polymorphism and prostate cancer risk in white and black American men. J Urol. 2006;176(2):793–6. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16813949]
  • Pooley KA, Tyrer J, Shah M, et al. No association between TERT-CLPTM1L single nucleotide polymorphism rs401681 and mean telomere length or cancer risk. Canc Epidemiol Biomarkers Prev. 2010;19(7):1862–5. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC2901592] [PubMed: 20570912]
  • Powell IJ, Zhou J, Sun Y, et al. CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy. J Urol. 2004;172(5 pt.1):1848–52. OVID-Embase. Exclude: Did not use SNP assembled panel. [PubMed: 15540736]
  • Prokunina-Olsson L, Fu YP, Tang W, et al. Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. Canc Epidemiol Biomarkers Prev. 2010;19(5):1349–55. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC2866032] [PubMed: 20406958]
  • Pugh TJ, Keyes M, Barclay L, et al. Sequence variant discovery in DNA repair genes from radiosensitive and radiotolerant prostate brachytherapy patients. Clin Canc Res. 2009;15(15):5008–16. OVID-Medline. Exclude: Candidate gene study. [PubMed: 19638463]
  • Purdie K, Gibbon K, Chaplin T, et al. High resolution genomic profiling of vulval neoplasia reveals genetic differences between human papillomavirus-associated and human papillomavirus-independent tumours. Journal of Investigative Dermatology; Conference: 41st Annual Meeting of the European Society for Dermatological Research, ESDR 2011; Barcelona Spain. 2011. p. S29. OVID-Embase. Exclude: Not about prostate cancer.
  • Qiu L, Wang Z, Shi X, et al. Associations between XPC polymorphisms and risk of cancers: A meta-analysis. Eur J Canc. 2008;44(15):2241–53. OVID-Medline. Exclude: Study Design. [PubMed: 18771913]
  • Rafnar T, Sulem P, Stacey SN, et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet. 2009;41(2):221–7. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 19151717]
  • Rancoita PM, Hutter M, Bertoni F, et al. An integrated Bayesian analysis of LOH and copy number data. BMC Bioinformatics. 2010;11:321. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC2912301] [PubMed: 20550648]
  • Ray AM, Zuhlke KA, Johnson GR, et al. Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families. Br J Canc. 2009;101(12):2043–7. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2795448] [PubMed: 19935797]
  • Ray AM, Zuhlke KA, Levin AM, et al. Sequence variation in the mitochondrial gene cytochrome c oxidase subunit I and prostate cancer in African American men. Prostate. 2009;69(9):956–60. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC2729404] [PubMed: 19267350]
  • Reams R, Kalari K, Wang H, et al. Detecting gene-gene interactions in prostate disease in African American men. Infect Agents Canc. 2011;6(Suppl 2):S1. OVID-Embase. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3194179] [PubMed: 21992608]
  • Rebbeck TR, Walker AH, Zeigler-Johnson C, et al. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet. 2000;67(4):1014–9. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC1287872] [PubMed: 10986046]
  • Rebbeck TR, Weber AL, Walker AH, et al. Context-dependent effects of genome-wide association study genotypes and macroenvironment on time to biochemical (prostate specific antigen) failure after prostatectomy. Canc Epidemiol Biomarkers Prev. 2010;19(9):2115–23. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC2972664] [PubMed: 20826827]
  • Reljic A, Simundic AM, Topic E, et al. The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and cancer risk: The Croatian case-control study. Clin Biochem. 2007;40(13-14):981–5. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17573062]
  • Rennert H, Zeigler-Johnson CM, Addya K, et al. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Canc Epidemiol Biomarkers Prev. 2005;14(4):949–57. OVID-Embase. Exclude: Test not commercially available. [PubMed: 15824169]
  • Ribeiro R, Vasconcelos A, Costa S, et al. Overexpressing leptin genetic polymorphism (-2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate. 2004;59(3):268–74. OVID-Medline. Exclude: Test not commercially available. [PubMed: 15042602]
  • Ricks-Santi L, Mason T, Apprey V, et al. p53 Pro72Arg polymorphism and prostate cancer in men of African descent. Prostate. 2010;70(16):1739–45. OVID-Medline. Exclude: No test panel of human SNP. [PMC free article: PMC3057117] [PubMed: 20593380]
  • Risio M, Venesio T, Kolomoets E, et al. Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers. Canc Epidemiol. 2011;35(4):e18–e24. OVID-Embase. Exclude: Did not use SNP assembled panel. [PubMed: 21094112]
  • Ritchey JD, Huang WY, Chokkalingam AP, et al. Genetic variants of DNA repair genes and prostate cancer: A population-based study. Canc Epidemiol Biomarkers Prev. 2005;14(7):1703–9. OVID-Embase. Exclude: Candidate gene study. [PubMed: 16030105]
  • Robbins C, Torres JB, Hooker S, et al. Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. Genome Res. 2007;17(12):1717–22. OVID-Embase. Exclude: Candidate gene study. [PMC free article: PMC2099580] [PubMed: 17978284]
  • Robbins CM, Hernandez W, Ahaghotu C, et al. Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases. Prostate. 2008;68(16):1790–7. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC4097307] [PubMed: 18767027]
  • Robbins CM, Hooker S, Kittles RA, et al. EphB2 SNPs and sporadic prostate cancer risk in African American men. PLoS One. 2011;6(5):e19494. OVID-Embase. Exclude: Candidate gene study. [PMC free article: PMC3095601] [PubMed: 21603658]
  • Rogler A, Rogenhofer M, Borchardt A, et al. P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: Association between disease onset and proline genotype. Pathobiology. 2011;78(4):193–200. OVID-Embase. Exclude: Test not commercially available. [PubMed: 21778786]
  • Romerius P, Giwercman A, Moell C, et al. Estrogen receptor alpha single nucleotide polymorphism modifies the risk of azoospermia in childhood cancer survivors. Pharmacogenetics Genom. 2011;21(5):263–9. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 21430602]
  • Ross PL, Cheng I, Liu X, et al. Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer. BMC Canc. 2009;9:69. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2657151] [PubMed: 19245716]
  • Ross RW, Oh WK, Xie W, et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008;26(6):842–7. OVID-Embase. Exclude: Candidate gene study. [PubMed: 18281655]
  • Rubin MA. Using molecular markers to predict outcome. J Urol. 2004;172(5 pt. 2):18–21. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 15535437]
  • Rukin NJ, Luscombe C, Moon S, et al. Prostate cancer susceptibility is mediated by interactions between exposure to ultraviolet radiation and polymorphisms in the 5' haplotype block of the vitamin D receptor gene. Canc Lett. 2007;247(2):328–35. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16815628]
  • Saenz-Lopez P, Carretero R, Cozar JM, et al. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Canc. 2008;19(8):382. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC2626602] [PubMed: 19099590]
  • Safarinejad MR, Shafiei N, Safarinejad S. Relationship between three polymorphisms of methylenetetrahydrofolate reductase (MTHFR C677T, A1298C, and G1793A) gene and risk of prostate cancer: A case-control study. Prostate. 2010;70(15):1645–57. OVID-Medline. Exclude: Test not commercially available. [PubMed: 20564317]
  • Salinas CA, Kwon E, Carlson CS, et al. Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk. Canc Epidemiol Biomarkers Prev. 2008;17(5):1203–13. OVID-Medline. Exclude: Candidate gene study. [PubMed: 18483343]
  • Santarius T, Bignell GR, Greenman CD, et al. GLO1 - A novel amplified gene in human cancer. Gene Chromosome Canc. 2010;49(8):711–25. OVID-Embase. Exclude: Not about prostate cancer. [PMC free article: PMC3398139] [PubMed: 20544845]
  • Sarma AV, Dunn RL, Lange LA, et al. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: The Flint Men's Health Study. Prostate. 2008;68(3):296–305. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2712831] [PubMed: 18163429]
  • Scariano JK, Treat E, Alba F, et al. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer. Prostate. 2008;68(16):1798–805. OVID-Medline. Exclude: SNP assessment in single gene. [PubMed: 18780294]
  • Schab M, Janiszewska H, Jarzemski P, et al. Frequency of CYP1B1 homozygous genotype 355T/T in prostate cancer families from Poland. Eur J Canc Prev. 2010;19(1):31–4. OVID-Medline. Exclude: Test not commercially available. [PubMed: 19820397]
  • Scheble VJ, Braun M, Beroukhim R, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol. 2010;23(8):1061–7. OVID-Embase. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3606550] [PubMed: 20473283]
  • Schirmer MA, Brockmoller J, Rave-Frank M, et al. A putatively functional haplotype in the gene encoding transforming growth factor beta-1 as a potential biomarker for radiosensitivity. Int J Radiat Oncol Biol Phys. 2011;79(3):866–74. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 21183289]
  • Schumacher FR, Feigelson HS, Cox DG, et al. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Canc Res. 2007;67(7):2951–6. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17409400]
  • Schumacher FR, Cheng I, Freedman ML, et al. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet. 2010;19(15):3089–101. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2901143] [PubMed: 20484221]
  • Schwab MM, Bollschweiler E, Warnecke-Eberz U, et al. Impact of MDR1 (C3435T) polymorphism on lymph node regression in multimodality treatment of upper GI cancer: Comparative analysis of patients with gastric cancer and adenocarcinoma of the esophagus. Langenbeck's Archives of Surgery; Conference: 15th Annual Meeting on Surgical Research; Dresden Germany. 2011. pp. 922–3. OVID-Embase. Exclude: Not about prostate cancer.
  • Schwartz GG, John EM, Rowland G, et al. Prostate cancer in African-American men and polymorphism in the calcium-sensing receptor. Canc Biol Ther. 2010;9(12):994–9. OVID-Embase. Exclude: No test panel of human SNP. [PubMed: 20364112]
  • Seppala EH, Autio V, Duggal P, et al. KLF6 IVS1 -27G>A variant and the risk of prostate cancer in Finland. Eur Urol. 2007;52(4):1076–81. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17125911]
  • Setiawan VW, Schumacher FR, Haiman CA, et al. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3) Canc Epidemiol Biomarkers Prev. 2007;16(11):2237–46. OVID-Medline. Exclude: Test not commercially available. [PubMed: 18006912]
  • Setlur SR, Chen CX, Hossain RR, et al. Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer. Canc Epidemiol Biomarkers Prev. 2010;19(1):229–39. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 20056642]
  • Severi G, Hayes VM, Padilla EJ, et al. The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: Results from an Australian population-based case-control study. Canc Epidemiol Biomarkers Prev. 2007;16(3):610–2. OVID-Medline. Exclude: No test panel of human SNP. [PubMed: 17372260]
  • Severi G, Hayes VM, Neufing P, et al. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. Canc Epidemiol Biomarkers Prev. 2006;15(6):1142–7. OVID-Embase. Exclude: SNP assessment in single gene. [PubMed: 16775173]
  • Sfar S, Saad H, Mosbah F, et al. Association of HSP70-hom genetic variant with prostate cancer risk. Mol Biol Rep. 2008;35(3):459–64. OVID-Medline. Exclude: No test panel of human SNP. [PubMed: 17578680]
  • Sfar S, Hassen E, Saad H, et al. Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine. 2006;35(1-2):21–8. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16908180]
  • Sfar S, Saad H, Mosbah F, et al. Combined effects of the angiogenic genes polymorphisms on prostate cancer susceptibility and aggressiveness. Mol Biol Rep. 2009;36(1):37–45. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17917789]
  • Sfar S, Saad H, Mosbah F, et al. Synergistic effect and VEGF/HSP70-hom haplotype analysis: Relationship to prostate cancer risk and clinical outcome. Hum Immunol. 2010;71(4):377–82. OVID-Medline. Exclude: Test not commercially available. [PubMed: 20096741]
  • Shahedi K, Lindstrom S, Zheng SL, et al. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Canc. 2006;119(3):668–72. OVID-Medline. Exclude: SNP assessment in single gene. [PubMed: 16506214]
  • Shao Y, Sun ZY, Sun SW, et al. Identification and expression analysis of novel LAGE-1 alleles with single nucleotide polymorphisms in cancer patients. J Canc Res Clin Oncol. 2008;134(4):495–502. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 17899192]
  • Sharma S, Cao X, Wilkens LR, et al. Well-done meat consumption, NAT1 and NAT2 acetylator genotypes and prostate cancer risk: The multiethnic cohort study. Canc Epidemiol Biomarkers Prev. 2010;19(7):1866–70. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC2901393] [PubMed: 20570911]
  • Shea PR, Ferrell RE, Patrick AL, et al. ELAC2 and prostate cancer risk in Afro-Caribbeans of Tobago. Hum Genet. 2002;111(4-5):398–400. OVID-Embase. Exclude: Test not commercially available. [PubMed: 12384782]
  • Shea PR, Ishwad CS, Bunker CH, et al. RNASEL and RNASEL-inhibitor variation and prostate cancer risk in Afro-Caribbeans. Prostate. 2008;68(4):354–9. OVID-Medline. Exclude: Test not commercially available. [PubMed: 18189233]
  • Shioji G, Ezura Y, Nakajima T, et al. Nucleotide variations in genes encoding plasminogen activator inhibitor-2 and serine proteinase inhibitor B10 associated with prostate cancer. J Hum Genet. 2005;50(10):507–15. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16172807]
  • Shook SJ, Beuten J, Torkko KC, et al. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin Canc Res. 2007;13(19):5959–64. OVID-Embase. Exclude: Test not commercially available. [PubMed: 17908993]
  • Sieh W, Edwards KL, Fitzpatrick AL, et al. Genetic susceptibility to prostate cancer: Prostate-specific antigen and its interaction with the androgen receptor (United States) Canc Causes Contr. 2006;17(2):187–97. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16425097]
  • Siemes C, Visser LE, de Jong FH, et al. Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer--The Rotterdam Study. Steroids. 2010;75(12):1024–32. OVID-Medline. Exclude: Test not commercially available. [PubMed: 20621111]
  • Siltanen S, Syrjakoski K, Fagerholm R, et al. ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer. Eur J Hum Genet. 2008;16(8):983–91. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC3404127] [PubMed: 18337727]
  • Singal R, Das PM, Manoharan M, et al. Polymorphisms in the DNA methyltransferase 3b gene and prostate cancer risk. Oncol Rep. 2005;14(2):569–73. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16012746]
  • Singal R, Ferdinand L, Das PM, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk. Int J Oncol. 2004;25(5):1465–71. OVID-Embase. Exclude: Test not commercially available. [PubMed: 15492840]
  • Sissung TM, Baum CE, Deeken J, et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Canc Res. 2008;14(14):4543–9. OVID-Embase. Exclude: Doesn't include test panel. [PMC free article: PMC2723795] [PubMed: 18628469]
  • Sissung TM, Danesi R, Price DK, et al. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Canc Therapeut. 2008;7(1):19–26. OVID-Embase. Exclude: Doesn't include test panel. [PubMed: 18187806]
  • Sobti RC, Onsory K, Al-Badran AI, et al. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol. 2006;25(5):287–94. OVID-Embase. Exclude: Test not commercially available. [PubMed: 16716118]
  • Soltysova A, Minarik G, Dzurenkova A, et al. APEX microarray panel for genotyping polymorphisms in cancer chemotherapy and estimation frequencies in a Slovak population. Pharmacogenomics. 2011;12(4):577–92. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 21521029]
  • Song H, Koessler T, Ahmed S, et al. Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer. Canc Res. 2008;68(21):8837–42. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC2666188] [PubMed: 18974127]
  • Song J, Kim DY, Kim CS, et al. The association between Toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in Korean men. Canc Genet Cytogenet. 2009;190(2):88–92. OVID-Medline. Exclude: Test not commercially available. [PubMed: 19380025]
  • Sorensen KD, Wild PJ, Mortezavi A, et al. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Canc Res. 2009;15(4):1400–10. OVID-Embase. Exclude: Study design. [PubMed: 19228741]
  • Souiden Y, Mahdouani M, Chaieb K, et al. CYP17 gene polymorphism and prostate cancer susceptibility in a Tunisian population. Canc Epidemiol. 2011;35(5):480–4. OVID-Embase. Exclude: Test not commercially available. [PubMed: 21193363]
  • Srivastava DS, Mandhani A, Mittal B, et al. Genetic polymorphism of glutathione S-transferase genes (GSTM1, GSTT1 and GSTP1) and susceptibility to prostate cancer in Northern India. BJU Int. 2005;95(1):170–3. OVID-Medline. Exclude: Test not commercially available. [PubMed: 15638917]
  • Srivastava K, Srivastava A, Kumar A, et al. Significant association between toll-like receptor gene polymorphisms and gallbladder cancer. Liver Int. 2010;30(7):1067–72. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 20492496]
  • Stanford JL, McDonnell SK, Friedrichsen DM, et al. Prostate cancer and genetic susceptibility: A genome scan incorporating disease aggressiveness. Prostate. 2006;66(3):317–25. OVID-Embase. Exclude: Did not use SNP assembled panel. [PubMed: 16245279]
  • Stark JR, Finn SP, Ma J, et al. Adiponectin receptor 2 expression predicts lethal prostate cancer. Lab Investig; Conference: United States and Canadian Academy of Pathology Annual Meeting, USCAP 2011; San Antonio, TX United States. 2011. p. 226A. OVID-Embase. Exclude: Study Design.
  • Stark JR, Wiklund F, Gronberg H, et al. Toll-like receptor signaling pathway variants and prostate cancer mortality. Canc Epidemiol Biomarkers Prev. 2009;18(6):1859–63. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2833418] [PubMed: 19505919]
  • Steeghs N, Gelderblom H, Wessels J, et al. Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors. Investig New Drugs. 2011;29(1):137–43. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC3016151] [PubMed: 19924384]
  • Stehr H, Jang SH, Duarte JM, et al. The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors. Mol Canc. 2011;10:54. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC3123651] [PubMed: 21575214]
  • Steinbrecher A, Meplan C, Hesketh J, et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Canc Epidemiol Biomarkers Prev. 2010;19(11):2958–68. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 20852007]
  • Stevens VL, Hsing AW, Talbot JT, et al. Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int J Canc. 2008;123(11):2644–50. OVID-Medline. Exclude: Candidate gene study. [PubMed: 18752252]
  • Stevens VL, Ahn J, Sun J, et al. HNF1B and JAZF1 genes, diabetes, and prostate cancer risk. Prostate. 2010;70(6):601–7. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3086139] [PubMed: 19998368]
  • Stevens VL, Rodriguez C, Sun J, et al. No association of single nucleotide polymorphisms in one-carbon metabolism genes with prostate cancer risk. Canc Epidemiol Biomarkers Prev. 2008;17(12):3612–4. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2645230] [PubMed: 19064578]
  • Stevens VL, Rodriguez C, Talbot JT, et al. Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS-II Nutrition Cohort. Prostate. 2008;68(12):1336–40. OVID-Medline. Exclude: Test not commercially available. [PubMed: 18500687]
  • Stiblar-Martincic D, Hajdinjak T. Polymorphism L26V in the cathepsin B gene may be associated with a risk of prostate cancer and differentiation. J Int Med Res. 2009;37(5):1604–10. OVID-Medline. Exclude: Test not commercially available. [PubMed: 19930869]
  • Stoehr R, Hitzenbichler F, Kneitz B, et al. Mdm2-SNP309 polymorphism in prostate cancer: No evidence for association with increased risk or histopathological tumour characteristics. Br J Canc. 2008;99(1):78–82. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2453021] [PubMed: 18577987]
  • Strawbridge RJ, Nister M, Brismar K, et al. Influence of MUC1 genetic variation on prostate cancer risk and survival. Eur J Hum Genet. 2008;16(12):1521–5. OVID-Embase. Exclude: SNP assessment in single gene. [PubMed: 18628787]
  • Strawbridge RJ, Nister M, Brismar K, et al. MUC1 as a putative prognostic marker for prostate cancer. Biomarker Insights. 2008;2008(3):303–15. OVID-Embase. Exclude: SNP assessment in single gene. [PMC free article: PMC2688377] [PubMed: 19578514]
  • Suarez BK, Pal P, Jin CH, et al. TGFBR1*6A is not associated with prostate cancer in men of European ancestry. Prostate Canc P Dis. 2005;8(1):50–3. OVID-Embase. Exclude: Test not commercially available. [PubMed: 15505640]
  • Suga T, Iwakawa M, Tsuji H, et al. Influence of multiple genetic polymorphisms on genitourinary morbidity after carbon ion radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72(3):808–13. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 18374504]
  • Sugiyama E, Kaniwa N, Kim SR, et al. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: Impact of genetic polymorphisms. Clin Pharmacokinet. 2010;49(8):549–58. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 20608756]
  • Suikki HE, Kujala PM, Tammela TL, et al. Genetic alterations and changes in expression of histone demethylases in prostate cancer. Prostate. 2010;70(8):889–98. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 20127736]
  • Sun J, Purcell L, Gao Z, et al. Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate. 2008;68(7):691–7. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3176499] [PubMed: 18361410]
  • Sun J, Zheng SL, Wiklund F, et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet. 2008;40(10):1153–5. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC3188432] [PubMed: 18758462]
  • Sun J, Wiklund F, Hsu FC, et al. Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the Toll-like receptor 6-1-10 gene cluster increase prostate cancer risk. Canc Epidemiol Biomarkers Prev. 2006;15(3):480–5. OVID-Embase. Exclude: Candidate gene study. [PubMed: 16537705]
  • Sun J, Hedelin M, Zheng SL, et al. Interleukin-6 sequence variants are not associated with prostate cancer risk. Canc Epidemiol Biomarkers Prev. 2004;13(10):1677–9. OVID-Embase. Exclude: SNP assessment in single gene. [PubMed: 15466986]
  • Sun J, Zheng SL, Wiklund F, et al. Sequence variants at 22q13 are associated with prostate cancer risk. Canc Res. 2009;69(1):10–5. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2705898] [PubMed: 19117981]
  • Sun J, Wiklund F, Zheng SL, et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Canc Inst. 2005;97(7):525–32. OVID-Medline. Exclude: Candidate gene study. [PubMed: 15812078]
  • Sun T, Zhou Y, Yang M, et al. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Canc Res. 2008;68(17):7025–34. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 18757416]
  • Sun T, Lee GS, Oh WK, et al. Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. Clin Canc Res. 2011;17(6):1546–52. OVID-Embase. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3060307] [PubMed: 21135144]
  • Sun T, Lee GS, Werner L, et al. Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Canc Epidemiol Biomarkers Prev. 2010;19(7):1871–8. OVID-Embase. Exclude: Candidate gene study. [PMC free article: PMC3755451] [PubMed: 20615892]
  • Sun T, Lee GS, Oh WK, et al. Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Canc Res. 2010;16(21):5244–51. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC2970725] [PubMed: 20855462]
  • Sun Y, Huang JT. Novel genetic loci associated with prostate cancer in the Japanese population. Asian J Androl. 2011;13(1):120–1. OVID-Medline. Exclude: Study Design. [PMC free article: PMC3739384] [PubMed: 20935669]
  • Suuriniemi M, Agalliu I, Schaid DJ, et al. Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Canc Epidemiol Biomarkers Prev. 2007;16(4):809–14. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17416775]
  • Suzuki K, Matsui H, Nakazato H, et al. Association of the genetic polymorphism in cytochrome P450 (CYP) 1A1 with risk of familial prostate cancer in a Japanese population: A case-control study. Canc Lett. 2003;195(2):177–83. OVID-Medline. Exclude: Test not commercially available. [PubMed: 12767526]
  • Suzuki K, Nakazato H, Matsui H, et al. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Canc. 2003;98(7):1411–6. OVID-Embase. Exclude: Test not commercially available. [PubMed: 14508827]
  • Suzuki M, Muto S, Hara K, et al. Single-nucleotide polymorphisms in the 17beta-hydroxysteroid dehydrogenase genes might predict the risk of side-effects of estramustine phosphate sodium in prostate cancer patients. Int J Urol. 2005;12(2):166–72. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 15733111]
  • Suzuki M, Mamun MRI, Hara K, et al. The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate. Eur Urol. 2005;48(5):752–9. OVID-Embase. Exclude: Test not commercially available. [PubMed: 16126332]
  • Suzuki M, Kurosaki T, Arai T, et al. The Val158Met polymorphism of the catechol-O-methyltransferase gene is not associated with the risk of sporadic or latent prostate cancer in Japanese men. Int J Urol. 2007;14(9):800–4. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17760745]
  • Suzuki MLM, Kurosaki T, Suzuki M, et al. Association of rs6983561 polymorphism at 8q24 with prostate cancer mortality in a Japanese population. Clin Genitourin Canc. 2011;9(1):46–52. OVID-Embase. Exclude: Did not use SNP assembled panel. [PubMed: 21700508]
  • Taioli E, Flores-Obando RE, Agalliu I, et al. Multi-institutional prostate cancer study of genetic susceptibility in populations of African descent. Carcinogenesis. 2011;32(9):1361–5. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC3165127] [PubMed: 21705483]
  • Tajtakova M, Pidanicova A, Valansky L, et al. Serum level of IGFBP3 and IGF1/IGFBP3 molar ratio in addition to PSA and single nucleotide polymorphism in PSA and CYP17 gene may contribute to early diagnostics of prostate cancer. Neoplasma. 2010;57(2):118–22. OVID-Medline. Exclude: Test not commercially available. [PubMed: 20099974]
  • Tan YC, Zeigler-Johnson C, Mittal RD, et al. Common 8q24 sequence variations are associated with Asian Indian advanced prostate cancer risk. Canc Epidemiol Biomarkers Prev. 2008;17(9):2431–5. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC3074274] [PubMed: 18768513]
  • Tayeb MT, Clark C, Haites NE, et al. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Canc. 2003;88(6):928–32. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2377095] [PubMed: 12644831]
  • Teixeira AL, Ribeiro R, Morais A, et al. Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. Pharmacogenomics J. 2009;9(5):341–6. OVID-Medline. Exclude: Test not commercially available. [PubMed: 19488063]
  • Teixeira AL, Ribeiro R, Cardoso D, et al. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Canc Res. 2008;14(11):3367–71. OVID-Medline. Exclude: Test not commercially available. [PubMed: 18519765]
  • Terada N, Tsuchiya N, Ma Z, et al. Association of genetic polymorphisms at 8q24 with the risk of prostate cancer in a Japanese population. Prostate. 2008;68(15):1689–95. OVID-Medline. Exclude: Test not commercially available. [PubMed: 18726982]
  • Thellenberg-Karlsson C, Lindstrom S, Malmer B, et al. Estrogen receptor beta polymorphism is associated with prostate cancer risk. Clin Canc Res. 2006;12(6):1936–41. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16551880]
  • Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008;40(3):310–5. OVID-Medline. Exclude: GWA study. [PubMed: 18264096]
  • Tian T, Xu Y, Dai J, et al. Functional polymorphisms in two pre-microRNAs and cancer risk: A meta-analysis. Int J Mol Epidemiol Genet. 2010;1(4):358–66. OVID-Embase. Exclude: Study Design. [PMC free article: PMC3076781] [PubMed: 21532845]
  • Tindall EA, Severi G, Hoang HN, et al. Comprehensive analysis of the cytokine-rich chromosome 5q31.1 region suggests a role for IL-4 gene variants in prostate cancer risk. Carcinogenesis. 2010;31(10):1748–54. OVID-Medline. Exclude: Test not commercially available. [PubMed: 20403914]
  • Tischkowitz MD, Yilmaz A, Chen LQ, et al. Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Canc Lett. 2008;270(1):173–80. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2969172] [PubMed: 18571837]
  • Torkko KC, van BA, Mai P, et al. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Clin Canc Res. 2008;14(10):3223–9. OVID-Embase. Exclude: Test not commercially available. [PubMed: 18483391]
  • Torniainen S, Hedelin M, Autio V, et al. Lactase persistence, dietary intake of milk, and the risk for prostate cancer in Sweden and Finland. Canc Epidemiol Biomarkers Prev. 2007;16(5):956–61. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17507622]
  • Torring N, Borre M, Sorensen KD, et al. Genome-wide analysis of allelic imbalance in prostate cancer using the Affymetrix 50K SNP mapping array. Br J Canc. 2007;96(3):499–506. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2360016] [PubMed: 17245344]
  • Travis RC, Schumacher F, Hirschhorn JN, et al. CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium. Canc Epidemiol Biomarkers Prev. 2009;18(10):2734–44. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2812905] [PubMed: 19789370]
  • Tsuchiya N, Mishina M, Narita S, et al. Association of XRCC1 gene polymorphisms with the susceptibility and chromosomal aberration of testicular germ cell tumors. Int J Oncol. 2006;28(5):1217–23. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 16596238]
  • Tsuchiya N, Wang L, Horikawa Y, et al. CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. Int J Oncol. 2005;26(1):225–31. OVID-Embase. Exclude: Test not commercially available. [PubMed: 15586244]
  • Urien S, Doz F, Giraud C, et al. Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect. Canc Chemother Pharmacol. 2011;67(3):597–603. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 20490798]
  • Vaarala MH, Mattila H, Ohtonen P, et al. The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer. Int J Canc. 2008;122(11):2511–6. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 18306354]
  • Valdman A, Nordenskjold A, Fang X, et al. Mutation analysis of the BRG1 gene in prostate cancer clinical samples. Int J Oncol. 2003;22(5):1003–7. OVID-Medline. Exclude: Did not use SNP assembled panel. [PubMed: 12684665]
  • Valva P, Becker P, Streitemberger P, et al. Germline TP53 mutations and single nucleotide polymorphisms in children. Medicina. 2009;69(1:Pt 2):143–7. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 19414295]
  • van Bemmel DM, Li Y, McLean J, et al. Blood lead levels, ALAD gene polymorphisms, and mortality. Epidemiol. 2011;22(2):273–8. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC3932657] [PubMed: 21293208]
  • VanCleave TT, Moore JH, Benford ML, et al. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate. 2010;70(4):341–52. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC4433472] [PubMed: 19908237]
  • Vazina A, Baniel J, Yaacobi Y, et al. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Canc. 2000;83(4):463–6. OVID-Embase. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2374645] [PubMed: 10945492]
  • Vijai J, Kirchhoff T, Gallagher D, et al. Genetic architecture of prostate cancer in the Ashkenazi Jewish population. Br J Canc. 2011;105(6):864–9. OVID-Embase. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3171013] [PubMed: 21829199]
  • Vijayalakshmi K, Vettriselvi V, Krishnan M, et al. Cytochrome p4501A1 gene variants as susceptibility marker for prostate cancer. Canc Biomarkers. 2005;1(4-5):251–8. OVID-Embase. Exclude: Test not commercially available. [PubMed: 17192049]
  • Vijayalakshmi K, Vettriselvi V, Krishnan M, et al. Polymorphisms at GSTM1 and GSTP1 gene loci and risk of prostate cancer in a South Indian population. Asian Pac J Canc Prev. 2005;6(3):309–14. OVID-Embase. Exclude: Test not commercially available. [PubMed: 16235991]
  • Wadsworth A, Dixon PH, Zabron AA, et al. Genetic variation in natural killer cell receptor protein G2D does not modify susceptibility to sporadic cholangiocarcinoma. Gut; Conference: Annual General Meeting of the British Society of Gastroenterology; Birmingham United Kingdom. 2011. p. A117. OVID-Embase. Exclude: Not about prostate cancer.
  • Wan Y, Wu W, Yin Z, et al. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: An updated meta-analysis. BMC Canc. 2011;11:208. OVID-Medline. Exclude: Study Design. [PMC free article: PMC3115916] [PubMed: 21619694]
  • Wang L, McDonnell SK, Hebbring SJ, et al. Polymorphisms in mitochondrial genes and prostate cancer risk. Canc Epidemiol Biomarkers Prev. 2008;17(12):3558–66. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2750891] [PubMed: 19064571]
  • Wang L, McDonnell SK, Slusser JP, et al. Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Canc Res. 2007;67(7):2944–50. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17409399]
  • Wang MH, Helzlsouer KJ, Smith MW, et al. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate. 2009;69(8):874–85. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC3016874] [PubMed: 19267370]
  • Wang T, Chen YH, Hong H, et al. Increased nucleotide polymorphic changes in the 5'-untranslated region of delta-catenin (CTNND2) gene in prostate cancer. Oncogene. 2009;28(4):555–64. OVID-Medline. Exclude: Doesn't include test panel. [PMC free article: PMC2678952] [PubMed: 18978817]
  • Wang W, Yuasa T, Tsuchiya N, et al. The novel tumor-suppressor Mel-18 in prostate cancer: Its functional polymorphism, expression and clinical significance. Int J Canc. 2009;125(12):2836–43. OVID-Medline. Exclude: Test not commercially available. [PubMed: 19585577]
  • Wang Y, Ray AM, Johnson EK, et al. Evidence for an association between prostate cancer and chromosome 8q24 and 10q11 genetic variants in African American men: The Flint Men's Health Study. Prostate. 2011;71(3):225–31. OVID-Medline. Exclude: Test not commercially available. [PubMed: 20717903]
  • Watanabe M, Hirokawa Y, Tsuji M, et al. Lack of involvement of the GNAS1 T393C polymorphism in prostate cancer risk in a Japanese population. Anticancer Res. 2008;28(6A):3711–6. OVID-Medline. Exclude: Test not commercially available. [PubMed: 19189654]
  • Waters KM, Wilkens LR, Monroe KR, et al. No association of type 2 diabetes risk variants and prostate cancer risk: The multiethnic cohort and PAGE. Canc Epidemiol Biomarkers Prev. 2011;20(9):1979–81. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC3175821] [PubMed: 21750171]
  • Wei B, Zhang Y, Xi B, et al. CYP17 T27C polymorphism and prostate cancer risk: A meta-analysis based on 31 studies. J Biomed Res. 2010;24(3):233–41. OVID-Embase. Exclude: Study Design. [PMC free article: PMC3596559] [PubMed: 23554635]
  • Wheeler DA. Mutation profiling in human cancer using next generation sequencing. Environ Mol Mutagen; Conference: 41st Annual Meeting of the Environmental Mutagen Society: Complex Systems in Biology and Risk Assessment Fort Worth; TX United States. 2010. p. 691. OVID-Embase. Exclude: Study Design.
  • Whitman EJ, Pomerantz M, Chen Y, et al. Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy. Canc Epidemiol Biomarkers Prev. 2010;19(1):1–8. OVID-Medline. Exclude: Doesn't include test panel. [PubMed: 20056617]
  • Wiklund F, Zheng SL, Sun J, et al. Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate. 2009;69(4):419–27. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC3348520] [PubMed: 19116992]
  • Wiklund F, Jonsson BA, Brookes AJ, et al. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Canc Res. 2004;10(21):7150–6. OVID-Medline. Exclude: Test not commercially available. [PubMed: 15534086]
  • Wilborn TW, Lang NP, Smith M, et al. Association of SULT2A1 allelic variants with plasma adrenal androgens and prostate cancer in African American men. J Steroid Biochem Mol Biol. 2006;99(4-5):209–14. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16617014]
  • Wo X, Han D, Sun H, et al. MDM2 SNP309 contributes to tumor susceptibility: A meta-analysis. J Genet Genom. 2011;38(8):341–50. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 21867960]
  • Wojnowski L, Hustert E, Klein K, et al. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Canc Inst. 2002;94(8):630–1. OVID-Medline. Exclude: No test panel of human SNP. [PubMed: 11959896]
  • Wokolorczyk D, Gliniewicz B, Sikorski A, et al. A range of cancers is associated with the rs6983267 marker on chromosome 8. Canc Res. 2008;68(23):9982–6. OVID-Medline. Exclude: Test not commercially available. [PubMed: 19047180]
  • Wokolorczyk D, Gliniewicz B, Stojewski M, et al. The rs1447295 and DG8S737 markers on chromosome 8q24 and cancer risk in the Polish population. Eur J Canc Prev. 2010;19(2):167–71. OVID-Medline. Exclude: Test not commercially available. [PubMed: 19952762]
  • Wolf S, Mertens D, Pscherer A, et al. Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Canc. 2006;118(7):1831–5. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16217763]
  • Wright JL, Neuhouser ML, Lin DW, et al. AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk. Prostate. 2011;71(5):498–506. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC3148811] [PubMed: 20945498]
  • Wright JL, Kwon EM, Lin DW, et al. CYP17 polymorphisms and prostate cancer outcomes. Prostate. 2010;70(10):1094–101. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2878282] [PubMed: 20503394]
  • Wright JL, Kwon EM, Ostrander EA, et al. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Canc Epidemiol Biomarkers Prev. 2011;20(4):619–27. OVID-Embase. Exclude: Candidate gene study. [PMC free article: PMC3073610] [PubMed: 21266523]
  • Wright ME, Peters U, Gunter MJ, et al. Association of variants in two vitamin e transport genes with circulating vitamin e concentrations and prostate cancer risk. Canc Res. 2009;69(4):1429–38. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2644342] [PubMed: 19190344]
  • Wu HC, Chang CH, Ke HL, et al. Association of cyclooxygenase 2 polymorphic genotypes with prostate cancer in Taiwan. Anticancer Res. 2011;31(1):221–5. OVID-Medline. Exclude: SNP assessment in single gene. [PubMed: 21273602]
  • Wu HC, Chang CH, Wan L, et al. IL-2 gene C/T polymorphism is associated with prostate cancer. J Clin Lab Anal. 2006;20(6):245–9. OVID-Medline. Exclude: Test not commercially available. [PubMed: 17115417]
  • Wu HC, Chang CH, Tsou YA, et al. Significant association of caveolin-1 (CAV1) genotypes with prostate cancer susceptibility in Taiwan. Anticancer Res. 2011;31(2):745–9. OVID-Medline. Exclude: Test not commercially available. [PubMed: 21378366]
  • Wu HC, Chang CH, Tsai RY, et al. Significant association of methylenetetrahydrofolate reductase single nucleotide polymorphisms with prostate cancer susceptibility in Taiwan. Anticancer Res. 2010;30(9):3573–7. OVID-Medline. Exclude: Test not commercially available. [PubMed: 20944139]
  • Wu M, Jolicoeur N, Li Z, et al. Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis. 2008;29(9):1710–6. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 18356149]
  • Xu B, Wang J, Tong N, et al. A functional polymorphism in MSMB gene promoter is associated with prostate cancer risk and serum MSMB expression. Prostate. 2010;70(10):1146–52. OVID-Medline. Exclude: Test not commercially available. [PubMed: 20333697]
  • Xu B, Feng NH, Li PC, et al. A functional polymorphism in Pre-miR-146a gene is associated with prostate cancer risk and mature miR-146a expression in vivo. Prostate. 2010;70(5):467–72. OVID-Embase. Exclude: Test not commercially available. [PubMed: 19902466]
  • Xu B, Xu Z, Cheng G, et al. Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern. Chinese Canc Genet Cytogenet. 2010;202(2):76–81. OVID-Medline. Exclude: Test not commercially available. [PubMed: 20875869]
  • Xu B, Niu XB, Wang ZD, et al. IL-6 -174G>C polymorphism and cancer risk: A meta-analysis involving 29,377 cases and 37,739 controls. Mol Biol Rep. 2011;38(4):2589–96. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 21104146]
  • Xu B, Mi YY, Min ZC, et al. p53 codon 72 increased biochemical recurrence risk after radical prostatectomy in a southern Chinese population. Urol Int. 2010;85(4):401–5. OVID-Medline. Exclude: Test not commercially available. [PubMed: 20664183]
  • Xu B, Feng NH, Tong N, et al. VEGF-460C>T polymorphism and cancer risk: A meta-analysis. Med Oncol. 2010;27(4):1031–6. OVID-Embase. Exclude: Study Design. [PubMed: 19816815]
  • Xu J, Isaacs SD, Sun J, et al. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Canc Res. 2008;14(18):5819–24. OVID-Medline. Exclude: Doesn't include test panel. [PMC free article: PMC2810539] [PubMed: 18794092]
  • Xu J, Meyers DA, Sterling DA, et al. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. Canc Epidemiol Biomarkers Prev. 2002;11(7):664–9. OVID-Medline. Exclude: Study design. [PubMed: 12101115]
  • Xu J, Zheng SL, Turner A, et al. Associations between hOGG1 sequence variants and prostate cancer susceptibility. Canc Res. 2002;62(8):2253–7. OVID-Medline. Exclude: SNP assessment in single gene. [PubMed: 11956079]
  • Xu J, Zheng SL, Komiya A, et al. Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Am J Hum Genet. 2003;72(1):208–12. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC378627] [PubMed: 12471593]
  • Xu J, Zheng SL, Carpten JD, et al. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet. 2001;68(4):901–11. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC1275644] [PubMed: 11254448]
  • Xu J, Zheng SL, Komiya A, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet. 2002;32(2):321–5. OVID-Embase. Exclude: Test not commercially available. [PubMed: 12244320]
  • Xu J, Zheng SL, Isaacs SD, et al. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci USA. 2010;107(5):2136–40. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2836698] [PubMed: 20080650]
  • Xu J, Zheng SL, Hawkins GA, et al. Linkage and association studies of prostate cancer susceptibility: Evidence for linkage at 8p22-23. Am J Hum Genet. 2001;69(2):341–50. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC1235306] [PubMed: 11443539]
  • Xu J, Kibel AS, Hu JJ, et al. Prostate cancer risk associated loci in African Americans. Canc Epidemiol Biomarkers Prev. 2009;18(7):2145–9. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2729762] [PubMed: 19549807]
  • Xu J, Lowey J, Wiklund F, et al. The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Canc Epidemiol Biomarkers Prev. 2005;14(11 pt. 1):2563–8. OVID-Medline. Exclude: Candidate gene study. [PubMed: 16284379]
  • Xu W, Xu J, Liu S, et al. Effects of common polymorphisms rs11614913 in mir-196a2 and rs2910164 in mir-146a on cancer susceptibility: A meta-analysis. PLoS One. 2011;6(5):e20471. OVID-Embase. Exclude: Study Design. [PMC free article: PMC3102728] [PubMed: 21637771]
  • Xu W, Li Y, Wang X, et al. PPARgamma polymorphisms and cancer risk: A meta-analysis involving 32,138 subjects. Oncol Rep. 2010;24(2):579–85. OVID-Embase. Exclude: Study Design. [PubMed: 20596649]
  • Xu WH, Zhang C, Zhao WM, et al. Mutational analysis of proto-oncogene Dbl on Xq27 in testicular germ cell tumors reveals a rare SNP in a patient with bilateral undescended testis. World J Urol. 2009;27(6):811–5. OVID-Embase. Exclude: Not about prostate cancer. [PubMed: 19373475]
  • Xu X, Valtonen-Andre C, Savblom C, et al. Polymorphisms at the microseminoprotein-beta locus associated with physiologic variation in beta-microseminoprotein and prostate-specific antigen levels. Canc Epidemiol Biomarkers Prev. 2010;19(8):2035–42. OVID-Embase. Exclude: SNP assessment in single gene. [PMC free article: PMC2946372] [PubMed: 20696662]
  • Yamada H, Penney KL, Takahashi H, et al. Replication of prostate cancer risk loci in a Japanese case-control association study. J Natl Canc Inst. 2009;101(19):1330–6. OVID-Medline. Exclude: GWA study. [PubMed: 19726753]
  • Yang HP, Woodson K, Taylor PR, et al. Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial. Eur J Canc Prev. 2006;15(3):249–53. OVID-Medline. Exclude: Test not commercially available. [PubMed: 16679868]
  • Yang J, Wu HF, Zhang W, et al. Polymorphisms of metabolic enzyme genes, living habits and prostate cancer susceptibility. Front Biosci. 2006;11(Suppl1):2052–60. OVID-Embase. Exclude: Test not commercially available. [PubMed: 16720291]
  • Yang L, Luo Y, Wei J. Integrative genomic analyses on Ikaros and its expression related to solid cancer prognosis. Oncol Rep. 2010;24(2):571–7. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 20596648]
  • Yang M, Xie W, Mostaghel E, et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011;29(18):2565–73. OVID-Embase. Exclude: Candidate gene study. [PMC free article: PMC3138634] [PubMed: 21606417]
  • Yaspan BL, McReynolds KM, Elmore JB, et al. A haplotype at chromosome Xq27.2 confers susceptibility to prostate cancer. Hum Genet. 2008;123(4):379–86. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2811403] [PubMed: 18350320]
  • Yeager M, Xiao N, Hayes RB, et al. Comprehensive resequence analysis of a 136 kb region of human chromosome 8q24 associated with prostate and colon cancers. Hum Genet. 2008;124(2):161–70. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC2525844] [PubMed: 18704501]
  • Yeager M, Deng Z, Boland J, et al. Comprehensive resequence analysis of a 97 kb region of chromosome 10q11.2 containing the MSMB gene associated with prostate cancer. Hum Genet. 2009;126(6):743–50. OVID-Embase. Exclude: Test not commercially available. [PMC free article: PMC2778717] [PubMed: 19644707]
  • Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007;39(5):645–9. OVID-Medline. Exclude: GWA study. [PubMed: 17401363]
  • Yeager M, Chatterjee N, Ciampa J, et al. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet. 2009;41(10):1055–7. OVID-Medline. Exclude: GWA study. [PMC free article: PMC3430510] [PubMed: 19767755]
  • Yokomizo A, Koga H, Kinukawa N, et al. Association of HER-2 polymorphism with Japanese sporadic prostate cancer susceptibility. Prostate. 2005;62(1):49–53. OVID-Medline. Exclude: No test panel of human SNP. [PubMed: 15389808]
  • Yokomizo A, Koga H, Kinukawa N, et al. HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer. Prostate. 2004;61(3):248–52. OVID-Medline. Exclude: Test not commercially available. [PubMed: 15368467]
  • Yoo KH, Kim SK, Chung JH, et al. Nitric oxide synthase 2 gene polymorphisms are associated with prostatic volume in Korean men with benign prostatic hyperplasia. Asian J Androl. 2010;12(5):690–6. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC3739311] [PubMed: 20562898]
  • Yoon KA, Gil HJ, Han J, et al. Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer. J Thorac Oncol. 2010;5(1):10–6. OVID-Medline. Exclude: Not about prostate cancer. [PubMed: 19901851]
  • Yu Z, Li Z, Jolicoeur N, et al. Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res. 2007;35(13):4535–41. OVID-Medline. Exclude: Not about prostate cancer. [PMC free article: PMC1935019] [PubMed: 17584784]
  • Zabaleta J, Su LJ, Lin HY, et al. Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis. 2009;30(8):1358–62. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2718072] [PubMed: 19474090]
  • Zabaleta J, Lin HY, Sierra RA, et al. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis. 2008;29(3):573–8. OVID-Medline. Exclude: Test not commercially available. [PubMed: 18174250]
  • Zacho J, Yazdanyar S, Bojesen SE, et al. Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C>T polymorphism and risk of cancer: Cross-sectional and prospective studies and meta-analyses of 75,000 cases and 93,000 controls. Int J Canc. 2011;128(3):644–52. OVID-Medline. Exclude: Study Design. [PubMed: 20473868]
  • Zeegers MP, Khan HS, Schouten LJ, et al. Genetic marker polymorphisms on chromosome 8q24 and prostate cancer in the Dutch population: DG8S737 may not be the causative variant. Eur J Hum Genet. 2011;19(1):118–20. OVID-Medline. Exclude: Test not commercially available. [PMC free article: PMC3039500] [PubMed: 20700145]
  • Zeigler-Johnson CM, Walker AH, Mancke B, et al. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered. 2002;54(1):13–21. OVID-Medline. Exclude: Test not commercially available. [PubMed: 12446983]
  • Zhang J, Dhakal IB, Lang NP, et al. Polymorphisms in inflammatory genes, plasma antioxidants, and prostate cancer risk. Canc Causes Contr. 2010;21(9):1437–44. OVID-Medline. Exclude: Candidate gene study. [PMC free article: PMC3207491] [PubMed: 20431935]
  • Zhang L, Shao N, Yu Q, et al. Association between p53 Pro72Arg polymorphism and prostate cancer risk: A meta-analysis. J Biomed Res. 2011;25(1):25–32. OVID-Embase. Exclude: Study Design. [PMC free article: PMC3596673] [PubMed: 23554668]
  • Zhang Y, Sturgis EM, Zafereo ME, et al. P14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Canc. 2011;117(6):1227–35. OVID-Embase. Exclude: Not about prostate cancer. [PMC free article: PMC3058845] [PubMed: 21381012]
  • Zheng SL, Liu W, Wiklund F, et al. A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Prostate. 2006;66(14):1556–64. OVID-Medline. Exclude: Candidate gene study. [PubMed: 16921508]
  • Zheng SL, Sun J, Cheng Y, et al. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Canc Inst. 2007;99(20):1525–33. OVID-Medline. Exclude: Candidate gene study. [PubMed: 17925536]
  • Zheng SL, Hsing AW, Sun J, et al. Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men. Prostate. 2010;70(4):425–32. OVID-Medline. Exclude: GWA study. [PMC free article: PMC3078699] [PubMed: 19866473]
  • Zheng SL, Mychaleckyj JC, Hawkins GA, et al. Evaluation of DLC1 as a prostate cancer susceptibility gene: Mutation screen and association study. Mutat Res. 2003;528(1-2):45–53. OVID-Medline. Exclude: Test not commercially available. [PubMed: 12873722]
  • Zheng SL, Chang BL, Faith DA, et al. Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk. Canc Res. 2002;62(22):6485–8. OVID-Embase. Exclude: SNP assessment in single gene. [PubMed: 12438241]
  • Zheng SL, Augustsson-Balter K, Chang B, et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: Results from. the CAncer Prostate in Sweden Study Canc Res. 2004;64(8):2918–22. OVID-Medline. Exclude: SNP assessment in single gene. [PubMed: 15087412]
  • Zheng SL, Stevens VL, Wiklund F, et al. Two independent prostate cancer risk-associated Loci at 11q13. Canc Epidemiol Biomarkers Prev. 2009;18(6):1815–20. OVID-Medline. Exclude: SNP assessment in single gene. [PMC free article: PMC2802212] [PubMed: 19505914]
  • Zhenhua L, Tsuchiya N, Narita S, et al. CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population. Canc Lett. 2005;225(2):237–43. OVID-Medline. Exclude: Test not commercially available. [PubMed: 15876487]
  • Zhu Y, Spitz MR, Amos CI, et al. An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. Canc Res. 2004;64(6):2251–7. OVID-Medline. Exclude: Study Design. [PubMed: 15026370]
  • Zhu Y, Stevens RG, Hoffman AE, et al. Testing the circadian gene hypothesis in prostate cancer: A population-based case-control study. Canc Res. 2009;69(24):9315–22. OVID-Medline. Exclude: Did not use SNP assembled panel. [PMC free article: PMC2955869] [PubMed: 19934327]
Bookshelf ID: NBK99069
PubReader format: click here to try

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.4M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to pubmed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...